

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12Q 1/68, C12N 15/10</b>		A2	(11) International Publication Number: <b>WO 00/46406</b> (43) International Publication Date: 10 August 2000 (10.08.00)
(21) International Application Number: PCT/US00/02974 (22) International Filing Date: 4 February 2000 (04.02.00)  (30) Priority Data: 60/118,901 5 February 1999 (05.02.99) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): ALPHAGENE, INC. [US/US]; 260 West Cummings, Woburn, MA 01801 (US).  (72) Inventors; and (75) Inventors/Applicants (for US only): YUAN, Olive, Yi-Lu [US/US]; 292 Mystic Street, Arlington, MA 02474 (US). VALENZUELA, Dario [CL/US]; 347 Lowell Street, 3rd Floor, Sommerville, MA 02145 (US). RAPEJKO, Peter [US/US]; 63 Old Grafton Road, Upton, MA 01568 (US). HOFFMANN, Heidi [US/US]; 90 Houghton's Mall Road, Lunenburg, MA 01462 (US). HIGGINS, Kara, Ann [US/US]; 13 Woodbury Road, Billerica, MA 01821 (US).  (74) Agents: HOGLE, Doreen, M. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>	

**(54) Title:** PROTEOMIC INTERACTION ARRAYS**(57) Abstract**

A method is provided for the rapid identification of protein-protein interaction networks within a cell, tissue, or whole genome. The introduction of a multi-bait approach is a distinguishing feature of the technology. In this method a pair of two-hybrid cDNA libraries, each one carrying the complement of genes from the tissue under study, are combined for an interaction screen. A large number of yeast colonies, each identifying a protein interaction pair, are picked and distributed in single wells, providing an arrayed archive of protein-protein interactions. The archive also serves as a source of plasmids to construct arrayed replicas containing DNA of the interacting plasmid pairs. Hybridization of a given cDNA to the arrayed replicas identifies the corresponding interacting clones. Protein interaction networks are constructed by iteration of the hybridization with newly identified interacting clones.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

## PROTEOMIC INTERACTION ARRAYS

### RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/118,901, filed February 5, 1999, the teachings of which are incorporated herein by reference in their entirety.

### BACKGROUND OF THE INVENTION

The identification of new pathways involving protein-protein interaction in disease states has a high commercial value because of their potential to identify therapeutic targets. A variety of procedures have been developed to identify interactions between proteins. Three common biochemical methods to screen for interacting proteins are, co-immunoprecipitation, affinity chromatography, and expression library screening. Coimmunoprecipitation is one of the most common biochemical methods to search for interacting proteins. For example, the well-known interaction between retinoblastoma protein (p110<sup>RB</sup>) and adenoviral protein E1A was obtained using this approach (Whyte *et al.*, *Nature* 334:124-129 (1988)). Affinity chromatography typically involves a bait protein linked to beads. Proteins that interact with a bait protein bind the bait and are eluted after washing the column. A typical application is to use glutathione-S-transferase protein (GST) fused to a polypeptide of interest as the bait protein. Expression library screening involves screening the library using a labeled bait protein as a probe. Expression library screening has been successful in identifying genes encoding proteins that interact with calmodulin, jun, myc, the EGF receptor and the retinoblastoma protein.

Although these methods have generated many significant results, they are all *in vitro* methods and are generally difficult to modify for high throughput. Furthermore, once the interacting proteins are identified, the cloning of its

corresponding gene could be very challenging and not easily engineered for high throughput analysis on discovery.

An *in vivo* genetic approach to detect protein-protein interactions is the yeast two-hybrid system. The two-hybrid system is typically applied to detect the 5 interaction between two proteins or to isolate interacting proteins from a library using a specific bait.

The two-hybrid system permits an *in vivo* identification of the interacting proteins. Hence, the conformation of the target protein in yeast cells is closer to the native form than most of the *in vitro* conditions that are available, and reasonably it 10 is therefore more likely to yield physiologically significant proteins. It is likely to be more sensitive for detection of protein-protein interaction than many other methods, such as probing an expression library with a labeled protein or co-immunoprecipitation, based on the parallel comparisons (Li *et al.*, *FASEB J.* 7:957-963 (1993)). This sensitivity allows the isolation of weaker or transiently interacting 15 proteins. Numerous protein interactions have been successfully detected by using the two-hybrid system, including cell cycle factors, signal transduction factors, proteins involved in apoptosis and DNA repair.

The use of the two-hybrid approach to determine protein-protein interaction rapidly and on a large scale has certain obstacles. Modification for high throughput 20 analysis of protein-protein interaction or high throughput identification of novel interacting proteins requires a tremendous amount of labor intensive subcloning of gene sequences of interest and sequencing of newly discovered candidate genes from libraries, making high throughput two-hybrid approaches time consuming and expensive. Traditionally, two-hybrid screens are performed using a single bait 25 protein, screening nucleic acids that encode potentially interacting proteins, retrieving the clones encoding the interacting proteins, sequencing these clones, and storing the sequence information *in silico*. The sequencing cost is extremely high when a genome-wide two-hybrid screen performed.

Furthermore, it has been estimated that the human genome encodes 100,000 30 proteins with potentially 50 billion different protein-protein interactions. However,

-3-

not all of these interactions are expected to be involved in pathways that are either involved in disease or development or are suitable drug targets. Thus, analysis of all two-hybrid interacting pairs involves considerable time, effort and expense for interactions that may have little or no commercial or research value.

5 Another limitation of the traditional two-hybrid approach has been the inability to reconstitute interactions mediated by several components or interactions that are dependent on specific post-translational modifications. Several assays have been described to overcome this barrier, including co-expression of a protein tyrosine kinase as a modifying enzyme to assess the interactions between  
10 phosphoproteins. However, these studies typically focus on a single bait protein and the interactions in the presence of the third protein, either as a modifier or stabilizer.

Further, limitations of the two-hybrid approach are the presence of false positives and false negatives. Although improvements have been implemented to reduce the number of false positives, the problem still exists. From the  
15 bacteriophage T7 protein linkage mapping project, it was found that the large majority of false positives appear to be due to transcriptional activation from the DNA binding domain clones in the absence of protein-protein interaction. That is to say, the DNA-binding domain hybrid (BD-X) activates the reporter gene by itself.  
In addition, false positives can result from the non-specific interaction via short  
20 stretches of residues.

## SUMMARY OF THE INVENTION

The present invention is drawn to a method of selecting nucleic acids encoding polypeptides, wherein the polypeptides are capable of interacting, *in vivo*  
25 (e.g., in a living cell) with a polypeptide of interest. The method comprises providing or generating an array of plasmid partners and probing the array with nucleic acid encoding a polypeptide of interest. Polynucleotides encoding a polypeptide that interacts with the polypeptide of interest are identified by contacting the array with polynucleotide probe encoding all or a portion of said  
30 polypeptide of interest under conditions where the probe detectably hybridizes to

-4-

complementary sequence, if present, within any of the plasmids of the array.

Plasmid partner or partners of the hybridized plasmid are identified and optionally isolated, wherein said partner or partners encode a polypeptide capable of interacting, under physiological conditions, with the polypeptide of interest.

5       The plasmid partners comprise two or more plasmids wherein each plasmid comprises a polynucleotide sequence encoding a polypeptide fused or linked to nucleic acid sequence encoding a DNA binding protein domain or a transcriptional activation domain. The plasmid partners are selected to be in the array by their ability to, in concert, produce a detectable biochemical readout, e.g., transcription of  
10 one or more marker genes in a host cell.

The present invention is drawn to a method of isolating polynucleic acids encoding at least one polypeptide capable of interacting, *in vivo* with a polypeptide of interest comprising:

a)       contacting at least one array of plasmids with a probe, wherein:  
15           i)       said probe encodes the polypeptide of interest or fragment thereof, wherein said probe hybridizes to complementary sequence, if present, within any of the plasmids, and wherein:  
             ii)      said array comprises two or more plasmid partners, wherein a first plasmid partner comprises a first library fused to a first nucleic acid sequence encoding a first half of a selection pair and a second plasmid partner comprises the same or a second library fused to a second nucleic acid sequence encoding a second half of a selection pair and wherein the plasmid partners are selected to be in the array by their ability to, in  
20           concert, activate the selection pair in a host cell, and  
25           b)       identifying the partner or partners to said hybridized plasmid, wherein said partner or partners encode a polypeptide capable of interacting, *in vivo* with the polypeptide of interest.

The present invention is drawn to a method of generating an array of  
30 plasmids comprising:

-5-

- a) conducting a two-hybrid screen, wherein bait plasmids comprise a cDNA library and a prey plasmids comprise the same or a second cDNA library;
- b) selecting positive two-hybrid clones and
- 5 c) immobilizing the bait and prey plasmids from said positive clones on a solid support at known locations, thereby generating an array of plasmids.

In another embodiment of the present invention, a method is provided for selecting polypeptides capable of interacting *in vivo* with a polypeptide of interest,

10 wherein the interaction is dependent upon post-translational modification. The method comprises providing or generating arrayed sets of plasmids comprising three or more plasmid partners, wherein a first plasmid partner comprises a library of sequences encoding polypeptides fused or linked to nucleic acid sequence encoding a DNA binding domain and wherein a second plasmid partner comprising the same  
15 or a second library fused or linked to nucleic acid encoding a transcriptional activation domain and wherein a third plasmid partner comprises at least one post-translational modifying enzyme. The expression of said enzyme is optionally under the control of an inducible transcription system. The first and second plasmid partners are selected by their ability, in concert, and in the presence of the expressed  
20 post-translational modifying enzyme, activate transcription of one or more marker genes in a host cell. Polypeptides that interact with the polypeptide of interest are selected by contacting nucleic acid encoding the polypeptide of interest to the array, under conditions where the nucleic acid detectably hybridizes to complementary sequence, if present, within any of plasmids. Plasmid partner or partners of the  
25 hybridized plasmid are identified and optionally isolated, wherein said partner or partners encode a polypeptide capable of interacting, *in vivo* and in a post-translational modification dependent manner, with the polypeptide of interest.

In another embodiment of the present invention, a method is provided for selecting polypeptides capable of interacting under physiological conditions, with a  
30 polypeptide of interest, wherein the interaction is inhibited by post-translational

-6-

modification. The method comprises providing or generating arrayed sets of plasmids comprising three or more plasmid partners, wherein a first and second plasmid partner as described above and a third plasmid partner comprising at least one post-translational modifying enzyme. The expression of said enzyme is 5 optionally under the control of an inducible transcription system. The first and second plasmid partners are selected by their ability to, in concert and in the absence of the post-translational modifying enzyme, activate transcription of one or more marker genes in a host cell. The array is probed with a polynucleotide encoding polypeptide of interest as described above.

10 The present invention provides a powerful tool to generate complete linkage map of proteins encoded by the cDNA library used to create the plasmid partner array. This information can be stored in the form of a DNA chip, avoiding the high cost of sequencing all clones. The method of the present invention is particularly suitable for high throughput operation. The archive of arrays of the present 15 invention allows identification and retrieval of the X, Y, or both sequences using standard hybridization techniques. A sequence of interest is used to probe the arrays of the linkage map by hybridization. A positive signal reveals both the sequence homologous to the probe as well as the partner plasmid. By using the linkage map of the present invention, one can probe the map with a sequence encoding a protein 20 of interest, which hybridizes selectively to complementary sequences, when present, in the X or Y inserts and find a corresponding plasmid that encodes a protein that interacts with the protein of interest. For example, if the sequence encoding the protein of interest hybridizes to X<sub>1</sub>, then the location of Y<sub>1</sub> in the array will be provided by the linkage map. The X<sub>1</sub> or Y<sub>1</sub>, sequence provided by the map can be 25 used to probe for other interacting proteins.

In the method of the present invention, any pair of DNA-binding domains and activation domains can be used. Furthermore, any site-specific transcription factor that has separable DNA binding domain and activation domain can be used. Other methods to identify protein-protein interactions in the two hybrid-derived 30 system include other reconstitutive methods whereby two domains that together

produce a biochemical readout can be physically separated such that the reassociation of the separated domains via protein X and Y interaction reconstitutes the biochemical readout; for example, as reviewed by Mendelsohn and Brent (the teachings of which are incorporated by reference herein in their entirety). The 5 membrane binding and catalytic domains of guanine exchange factor can be used (Mendelsohn and Brent, *Science* 284:1948-1950 (1999)). These separated domains are referred to herein as a first and second half of a selection pair, respectively.

The present invention is advantageous over other biochemical methods for a number of reasons. The present invention uses arrays to store all protein-protein 10 interaction information identified using two-hybrid screening without performing a large amount of subcloning or sequencing. Instead, the positively interacting pairs are identified using probes selected by the user to hybridize the array and identify all locations of the array that contain DNA encoding the protein of interest and partner plasmids in the same or linked array that encode proteins that interact with said 15 protein of interest. Therefore, the present invention significantly reduces the cost of mapping protein interactions on a cellular, tissue or genome wide scale. Moreover, the arrays of the present invention provide an archive in which a user can obtain the interaction partners rapidly by DNA hybridization; a much faster and simpler technique than yeast two-hybrid screen. A database of interacting partners can be 20 produced by storing the identity of partner pairs identified by hybridization in computer table. The modification of using different selection markers on bait and prey vectors in the two-hybrid system simplifies the plasmid DNA recovery process and speeds up the entire two-hybrid screening procedure. In addition, the process of generating the array, probing the array and identifying plasmids encoding interacting 25 pairs of proteins can be automated.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram of the generation of Proteomic Interaction Arrays.

-8-

Figure 2 is a diagram of two plasmids for use in the two-hybrid screen of the present invention.

Figure 3 is a schematic diagram of the generation of Proteomic Interaction Arrays using three protein, two-hybrid (3PTH).

5       Figure 4 shows the hybridization of vector sequences to the test array of Example 1.

Figure 5 shows the hybridization of an Snk probe to the test array of Example 1.

10     Figure 6 shows the hybridization of an B11 probe to the test array of Example 1.

#### DETAILED DESCRIPTION OF THE INVENTION

The human genome sequencing project has had a revolutionary effect on biological research. The decoding of all genes brings the blueprint of life to 15 scientists, while the function of genes still remains a mystery. Since virtually all cellular processes are controlled by proteins, including disease processes and developmental processes, knowledge of how proteins interact is necessary to understand these processes.

The present invention relates to a novel high throughput approach to two-20 hybrid analysis. The yeast two-hybrid system is a genetic approach which allows one to detect protein-protein interaction *in vivo* through the reconstitution of the activity of a transcriptional activator, such as GAL4, in yeast *Saccharomyces cerevisiae*. The key of the two-hybrid system is the finding that site-specific transcription factors are often modular, comprised of separable DNA-binding 25 domains (BDs) that bind to a specific promoter sequence, and activation domains (ADs) that direct the RNA polymerase II complex to transcribe the gene downstream of the DNA binding site. This phenomenon is exploited by fusing separate binding and activation domains to a pair of interacting proteins, X and Y, to create two hybrid proteins, BD-X and AD-Y. If the X and Y proteins interact, co-

expression of two hybrids in a yeast cell leads to expression of a reporter gene containing the cognate BD-binding site. This approach can be also used to isolate cDNAs encoding partners for a protein of interest from an AD-Y library.

The present invention is drawn to a genome-wide scale two-hybrid screen.

5 The method of the present invention involves a rapid plasmid retrieval system to recover plasmids from two-hybrid positive cells, an array system to store the interaction information using suitable substrates such as filter membranes or microarrays (eg. on glass slides), and a hybridization method to identify nucleic acid encoding proteins that interact with a polypeptide of interest. The present invention  
10 also relates to cDNA libraries constructed in suitable two-hybrid plasmids, such as the two plasmids shown in Figure 2.

The present invention is drawn to a method to quickly identify DNA encoding proteins which interact with a protein of interest, by probing the arrays of the present invention with nucleic acid encoding the protein of interest. The method  
15 involves construction of an array of protein-protein interactions represented by plasmid pairs, wherein the plasmid pairs have been selected from a genome-wide scale two-hybrid screen. The collection of plasmid pairs is referred to herein as an “interaction library” or array. In this embodiment, the first and second plasmid pairs are generated using the cDNA library from a cell line or tissue of interest. In  
20 another embodiment, the array represents the entire complement of protein-protein interactions of an organism. The present invention can also be applied to other screens, such as yeast three-hybrid, one-hybrid, and mammalian two-hybrid screen.

In the method of the present invention, positive yeast hybrids from the two-hybrid assay are selected and distributed in an array, such as a two dimensional array. The clones are also stored for future access. Each yeast hybrid is a clone containing at least two plasmids. To identify nucleic acid encoding polypeptides that interact with a polypeptide of interest, the plasmids from the yeast clone array are transferred to a solid support for hybridization screening. The plasmid array is probed with a nucleic acid selected by a user. In one embodiment, the nucleic acid  
30 encodes a protein of interest. The array is contacted with the probe under suitable

-10-

hybridization conditions. The wells or array locations containing nucleic acid homologous with specific probe are identified by hybridization with the probe. Vectors or plasmids encoding interacting partner(s) of the protein of interest are also identified. After identification of the vectors encoding interacting partners, the 5 process can be repeated with the newly identified polynucleic acid molecules to reveal polynucleic acids encoding proteins that interact with the previously identified interacting partners. Thus, the method and arrays of the present invention provide networks of interaction pathways within a cell.

The skilled artisan will recognize that factors commonly used to impose or 10 control stringency of hybridization include formamide concentration (or other chemical denaturant reagent), salt concentration (i.e., ionic strength), hybridization temperature, detergent concentration, pH and the presence or absence of chaotropes. Optimal stringency for a probe/target combination is often found by the well known technique of fixing several of the aforementioned stringency factors and then 15 determining the effect of varying a single stringency factor. Optimal stringency for hybridizing the user defined probe to the array may be experimentally determined by examining variations of each stringency factor until the desired degree of discrimination between specific and non-specific sequences has been achieved. The level of stringency will increase or decrease depending on whether the target and 20 variable regions are complementary or substantially complementary.

A general description of stringent hybridization conditions is provided in Ausubel, F.M., *et al.*, *Current Protocols in Molecular Biology*, Greene Publishing Assoc. and Wiley-Interscience 1989, the teachings of which are incorporated herein by reference. The influence of factors such as probe length, base composition, 25 percent mismatch between the hybridizing sequences, temperature and ionic strength on the stability of nucleic acid hybrids is well known in the art. Thus, stringency conditions sufficient to allow the user defined probes to hybridize with specificity to a homologous nucleic acid sequence, if present, in the array can be determined empirically. The probe need not hybridize to the nucleic acid sequence of interest

with exact complementarity, so long as the target nucleic acid sequence of interest is identical or nearly identical to the probe, e.g., a homologue or variant.

Conditions for stringency are also described in: Secreted Proteins and Polynucleotides Encoding Them, (Jacobs *et al.*, WO 98/40404), the teachings of which are incorporated herein by reference. In particular, examples of highly stringent, stringent, reduced and least stringent conditions are provided in WO 98/40404 in the Table on page 36. In one embodiment of the present invention, highly stringent conditions are those that are at least as stringent as, for example, 1x SSC at 65°C, or 1x SSC and 50% formamide at 42°C. Moderate stringency conditions are those that are at least as stringent as 4x SSC at 65°C, or 4x SSC and 50% formamide at 42°C. Reduced stringency conditions are those that are at least as stringent as 4x SSC at 50°C, or 6x SSC and 50% formamide at 40°C.

The present invention expedites the process of discovering novel interaction pathways while minimizing the need for subcloning or sequencing polynucleotides that do not encode proteins that interact with a polypeptide of interest.

Also provided by the present invention are two-hybrid plasmids, one containing the DNA-binding domain (first plasmid) and the other containing the activation domain (second plasmid). These two plasmids use two different *E. coli* selection markers. Useful selection markers for the present invention include for example, genes encoding ampicillin, kanamycin, chloramphenicol, tetracycline, Zeocine and trimethoprim resistance. In one embodiment, three selection markers can be used. For example, a unique selectable marker can be present on each of the plasmids, such as ampicillin on plasmid one and kanamycin on plasmid two, and a common selectable marker present on both plasmids. In another embodiment, one marker can be used a common marker present on both plasmids. The markers allow the isolation of the plasmids using techniques well known in the art. For example, the plasmids isolated from the two hybrid clone can be transformed into *E. coli* which are grown in the presence of the appropriate antibiotic. Plasmids are purified from the selected *E. coli* using standard techniques in the art. A common marker

-12-

would allow the isolation of both plasmids in a single step, saving time and expense involved in separate isolations.

In the method of the present invention, a protein-protein linkage map is generated and stored as an array, without the need for subcloning or sequencing the 5 X or Y inserts. The present invention also provides a proteomic array of interactive protein pairs, and nucleic acid encoding the pairs and is also referred to herein as an archive. The interactive protein pair information can be stored as a database comprising at least one of said arrays, coupled with information describing the linkage between the members of said array. For example, each selected two-hybrid 10 clone harbors a bait plasmid and a prey plasmid. These plasmids can be stored together in the same location of the two dimensional array, on the bait plasmids from all two-hybrid clones can be stored in one array or set of arrays while the prey plasmids are stored in a separate array or set of arrays. The bait and prey arrays will be linked by information such that identifying a given bait or prey plasmid reveals 15 the location of the corresponding prey or bait plasmid, respectively.

The arrays of the present invention can be of any suitable size on any suitable substrate. In one embodiment of the present invention, the arrays are two dimensional. In another embodiment, the substrate is a plastic tray or plate comprising wells, such as a 96 well or 384 well plate. Said plates are well known in 20 the art. In another embodiment, the array can be a series of spots on a substrate, such as nylon membrane, glass slide, or photolithographic biochip. The amount of DNA in a given spot can be as little as nanogram quantities, however, less can be used depending on the sensitivity of the detection system. The number of spots in an array can be very large depending on the resolution of the spotting or printing apparatus 25 used.

The two-hybrid systems and proteomic arrays of the present invention can be combined a microarray system. As a result, differentially expressed genes can be identified in normal or disease states, or at particular stages of development without having to examine 50 billion potential interactions. Methods of making microarrays 30 are well known in the art and methods of identifying differentially expressed genes is

described in U.S. Serial No. 09/350,609, the teachings of which are incorporated herein by reference in their entirety.

In another embodiment of the present invention, a method is provided for selecting polypeptides capable of interacting *in vivo* with a polypeptide of interest, 5 wherein the interaction is dependent upon post-translational modification (3 protein, two-hybrid). The method comprises providing or generating arrays comprising a first plasmid partner comprising a library linked to nucleic acid sequence encoding a DNA binding domain and a second plasmid partner comprising the same or a second library linked to nucleic acid encoding a transcriptional activation domain, wherein 10 the first and second plasmid partners encode proteins that interact in the presence but not the absence of the third plasmid partner comprising at least one post-translational modifying enzyme. The expression of said enzyme is optionally under the control of an inducible transcriptional system. The first and second plasmid partners are selected by their ability to, in concert and in the presence of the expressed post- 15 translational modifying enzyme, activate transcription of one or more marker genes in a host cell. In another embodiment, the first and second plasmid partners encode proteins that interact in the absence but not in the presence of the third plasmid partner.

Plasmids or vectors that encode all or a portion of a polypeptide of interest 20 and polypeptides that interact with the polypeptide of interest are selected by contacting the array under conditions where the probe detectably hybridizes to complementary sequence, if present, within any of plasmids of the array. Plasmid partner or partners of the hybridized plasmid are identified (e.g., localized on the array) and optionally isolated, wherein said partner or partners encode a polypeptide 25 capable of interacting, under physiological conditions and in a post-translational modification dependent manner, with the polypeptide of interest.

The post-translational modifiers selected for use in the third dimension of the 3PTH system can be selected from known genes encoding desired members of the family. For example, genes encoding several protein kinases have been cloned, such 30 as PKA, SYK, p34cdc2, PKC and PI3 kinase and can be readily used in the method

-14-

of the present invention by one of ordinary skill in the art. Similarly, genes for phosphatases, glycosylation enzymes and endoproteases have been cloned and can be readily used in the method of the present invention.

In another embodiment of the present invention, the modification enzyme  
5 encoded by the third plasmid is under the control of an inducible promoter such as MET25. Inducible promoters are well known in the art and can readily be incorporated into the method of the present invention. Other inducible systems include heat shock, GAL and tetracycline inducible promoter systems.

In one embodiment of the present invention, one or more post-translational  
10 enzymes are used in the third dimension of the 3PTH system. In a yet another embodiment of the present invention, the genes encoding post-translational modifiers of the third dimension can be a library of genes encoding such proteins. A family of kinases, proteases, glycosylation enzymes or endoproteases representing all or a portion of the cellular complement of such proteins can be generated, for example  
15 using PCR. For example, primers for PCR can be used that recognize known motifs in the class of post-translational modifier to be used in order to amplify all or a portion of the sequences encoding said modifiers. In one embodiment of the 3PTH method of the present invention, the third plasmid partner is not included in the arrays produced. In one embodiment, the first and second plasmid partners are  
20 selected using selective markers that is not present on the third plasmid partner.

In another embodiment, of the present invention, at least one plasmid partner is generated from a normalized library. Libraries can be normalized, for example, as described by Sive and St. John (Nucleic Acids Res. 16:10937 (1988)) and in U.S. Serial No.: 60/067,992 the teachings of which are both incorporated herein by  
25 reference in their entirety.

The plasmid partners can be generated by fusing the library sequences to DNA encoding one half of the selection complex e.g., the DNA binding domain sequence or transcription activation sequence such that a fusion protein comprising both segments is expressed. In one embodiment, the fusion is in frame between the  
30 coding sequence of both segments. However, libraries containing some out of frame

fusions can be used, in which case the library is generally made with more clones. In one embodiment of the present invention, the library of the first plasmid partner is fused at its 5' end to the sequence encoding a DNA binding protein. In another embodiment of the present invention, the library of the first plasmid partner is fused 5 at its 3' end to the sequence encoding a DNA binding protein. Similarly, the library of the second plasmid partner can be fused at either its 5' or 3' end to the sequence encoding the other half of the selection complex; for example, if the first plasmid partner uses the DNA binding domain, then the second plasmid partner uses the DNA transcription domain to generate the second plasmid partner.

10 In one embodiment of the present invention, the library comprises cDNA, full-length cDNA, genomic DNA or DNA encoding a peptide library. These libraries are readily available from commercial sources or can be synthesized using techniques well known in the art. For example, full length libraries are produced using methods described in U.S. Serial No. 09/062,452 the teachings of which are incorporated 15 herein by reference in their entirety.

The DNA binding protein and transcriptional activators used to generate the selection complex can be from any known transcriptional activation protein that binds DNA wherein the DNA binding domain binds in a sequence specific manner. Useful transcriptional activators are well known in the art. Particularly useful are 20 those proteins where in the DNA activation domain and the DNA binding domain are separable at the DNA sequence level. In a further embodiment of the present invention, the DNA binding protein domain is selected from the group consisting of GAL4, lexA, GCN4 and ADR1. In another embodiment of the present invention, the transcription activation domain is selected from the group consisting of GAL4, 25 GCN4, ADR1 and herpes simplex VP16.

The DNA binding site is typically placed upstream of a gene encoding a selectable marker for the host organism such that protein-protein interaction between the polypeptides encoded by the first and second partner plasmid results in transcription of the gene encoding the selectable marker. Selectable markers are well 30 known in the art and include, for example, genes that render the host prototrophic for

-16-

a given nutrient and genes that encode enzymes that produce a color or fluorescent product when exposed to the appropriate substrate.

In one embodiment, yeast clones harboring plasmid partners that encode interacting polypeptides are selected by growing the fused two-hybrid host on  
5 medium lacking the nutrient required in the absence of transcription of the gene encoding the selectable marker. In another embodiment the fused two-hybrid hosts are grown on medium containing the appropriate colorimetric or fluorogenic substrate for the enzyme encoded by the selectable marker gene.

The two-hybrid hosts can be fused in batch. In one embodiment, the fused  
10 two-hybrid hosts are plated on the selective medium such that individual colonies are derived from individual fused hosts. Positive clones can be picked or isolated by hand or by robotic methods. Colony picking robots are well known in the art. In another embodiment, the fused two-hybrid hosts are contacted with the fluorogenic substrate and positive cells are selected using a fluorescence activated cell sorter.  
15 Methods of fluorescence activated cell sorting are well known in the art.

Suitable hosts for the two-hybrid screen of the present invention include any transformable organism that can be grown as a single-celled organism. Such hosts include prokaryotes and eukaryotes. In particular eukaryotic hosts can be yeast and mammalian or other cell culture.

20 The arrays of the present invention can be generated using polynucleic acid libraries from any organism of interest, including prokaryotic, archebacterial and eukaryotic organisms.

The present invention is drawn to a composition comprising an array of plasmids comprising two or more plasmid partners wherein a first plasmid partner  
25 comprises a first library fused to a nucleic acid encoding a DNA binding domain, a second plasmid partner comprises the first or a second library fused to a nucleic acid sequence encoding a transcriptional activation domain, wherein the first and second plasmid partners are selected to be in the array by their ability to, in concert and in the absence of expression of said post-translational modifying enzyme, activate

transcription of one or more marker genes in a host cell, wherein the post-translational modifying enzyme is encoded by a third plasmid partner in the host cell.

The present invention is drawn to a composition comprising an array of plasmids comprising two or more plasmid partners wherein a first plasmid partner 5 comprises a first library fused to a nucleic acid encoding a DNA binding domain, a second plasmid partner comprises the first or a second library fused to a nucleic acid sequence encoding a transcriptional activation domain, wherein the first and second plasmid partners are selected to be in the array by their ability to, in concert and in the presence of expression of said post-translational modifying enzyme, activate 10 transcription of one or more marker genes in a host cell, wherein the post-translational modifying enzyme is encoded by a third plasmid partner in the host cell.

Methods for reducing the false negatives include making different libraries.

For example, random primed cDNA two-hybrid libraries can be constructed to obtain small protein domains which may be buried in the intact proteins in a specific 15 condition. Second, the protein fusion interface can be changed. Traditionally, the DNA binding domain and activation domain are located in the N-terminus of the fusion protein. New libraries can be constructed with the DNA binding domain and activation domain located at its C-terminus, so that the N-terminus of the bait protein can be free for its interactions. Third, the libraries for the first and second plasmid 20 partner can be enriched for full-length genes. Furthermore, several "cytoplasm two-hybrid systems" have been developed. Cytoplasm two-hybrid systems can be integrated into the 3PTH system to cover those proteins which do not interact properly in the nucleus.

The invention will be further illustrated by the following non-limiting 25 example.

-18-

## EXAMPLES

### Example 1: Three-Protein Two Hybrid Screen

#### Plasmid Vectors:

5 Two vectors with three drug resistance genes are constructed. Each vector carries an unique *E.coli* selection marker such as Zeocin or DHFR (DHFR represents DiHydroFolate Reductase and confers resistant to Trimethoprin). The vectors also carry an additional common selection marker,  $\beta$ -lactamase. The drug resistant gene specific to each vector increases the efficiency of recovering the plasmids that are  
10 positive. The cycloheximide counterselection system (Harper *et al.*, *Cell*, 75:805-816 (1993)) can be used to optimize selection.

The DNA-binding domain (DB) vector (or first plasmid partner) is constructed by inserting the Zeocin resistant gene into pGBT9 (Bartel *et al.*, *Methods Enzymol.*, 254:241-263 (1995)) or pDBTrp (Vidal, Bartel and Fields, Eds. Oxford Univ. Press 109, (1997)). pACT2 constitutes the basis of the activation domain (AD) vector (second plasmid partner) with the addition of the DHFR gene. pGBT9 and pDBTrp are selected because they yield low levels of false positives. While not wishing to be bound by theory, this may be due to their low level of gene expression.  
15 The main source of false positives usually originates from the activation of the DB-vector reporter gene by itself pDBTrp is a centromere-based (low copy number) expression plasmid with the full length ADH1 promoter. pGBT9 is a two micron-based (high copy number) expression vector with a truncation to give a minimal activity ADH1 promoter.  
20

#### 25 Yeast Strains:

The promoter strength of the reporter gene and the expression level of the two hybrid proteins determine the sensitivity of two-hybrid system. Thus, the selection of the yeast host strain is critical for success. In general, the upstream activating sequence (UAS) of GAL1 is stronger than GAL2 UAS , and GAL2 UAS is stronger  
30 than the synthetic GAL4 binding site consensus sequence (UAS G17-mer). The available host strains shown below are compared and the optimal pair is selected.

-19-

PJ69-2A: MAT<sub>a</sub>, trp1-901, leu2-3,112, ura3-52, his3-200, gal4, gal80,  
LYS2::GAL1<sub>UAS</sub>-GAL1<sub>TATA</sub>-HIS3, GAL2<sub>UAS</sub>-GAL2<sub>TATA</sub>-ADE2  
(James *et al.*, *Genetics* 144:1425-1436 (1996))

5 Y187: MAT<sub>a</sub>, ura3-52, his3-200, ade2-101, trp1-901, leu2-3,112, met-, gal4,  
gal80, URA3:: GAL1<sub>UAS</sub>-GAL1<sub>TATA</sub>-lacZ (Harper *et al.*, *Cell*, 75:805-  
816 (1993)).

MaV103: MAT<sub>a</sub>, leu2-3,112, trp1-901, his3\_200, ade2-101, gal4, gal80,  
10 SPAL10::URA3, GAL1(GAL1<sub>UAS</sub>)::lacZ, HIS3(GAL1<sub>UAS</sub>)::HIS3  
@LYS2 (Vidal *et al.*, *Proc. Natl. Acad. Sci. USA* 93:10315-10328  
(1996)).

MaV203: MAT<sub>a</sub>, leu2-3,112, trp1-901, his3\_200, ade2-101, gal4, gal80,  
15 SPAL10::URA3, GAL1(GAL1<sub>UAS</sub>)::lacZ, HIS3(GAL1<sub>UAS</sub>)::HIS3  
@LYS2 (Vidal, 1997 )

The host strain pair PJ69-2A /Y187 uses two different promoters (GAL1 and GAL2) on three different reporters (HIS3, ADE2, lacZ). The yeast pair MaV103 and  
20 MaV203 has SPAL10(UAS G17-mer) and GAL1 as the promoters in front of reporters URA3, HIS3, and lacZ. The sensitivity of SPAL10 (UAS G17-mer) promoter to GAL1 and GAL2 is compared by using a group of known interacting proteins with different affinities (Table I), then selecting the strain with stronger promoters.

25

-20-

TABLE I : Examples of Known Interacting Pairs

	Hybrid #1	Hybrid #2	Interaction Strength
5	Pair 1 human RB (aa302-928)	human E2F (aa342-437)	weak (Vidal <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA.</i> 93(19):10315-20 (1996))
	Pair 2 Drosophila DP (aa1-377)	Drosophila (aa225-433)	moderate (Du <i>et al.</i> , <i>Genes Dev.</i> 10(10):1206-18 (1996))
10	Pair 3 cFos (aa132-211)	cJun (aa250-325)	strong (Chevray & Nathans, <i>Proc. Natl. Acad. Sci., USA.</i> , 89 (13):5789-93 (1992))
	Pair 4 murine p53 (aa72-390)	SV40 T antigen (aa87-708)	moderate (Iwabuchi <i>et al.</i> , <i>Oncogene</i> , 8(6):1693-6 (1993))
15	Pair 5 yeast SNF1	yeast SNF4	weak (Fields & Song, <i>Nature</i> 340 : 245-6 (1989))
	Pair 6 murine SNK	human CIB	moderate (Yuan & Erikson, unpublished)

## Library Construction:

A series of brain cDNA libraries is constructed using AlphaGene's normalization and FLEX™ (Full-Length Expressed gene) cDNA library construction technologies U.S. Serial No.s: 09/062,452, the teachings of which are incorporated herein in their entirety. Plasmid pGBT9-Zeo has been constructed and tested by constructing a human fetal brain library with a titer of  $1.8 \times 10^6$  primary clones. The libraries were normalized. Table II summarizes the results of  $\alpha$ -tubulin and  $\beta$ -actin abundance comparisons in two cDNA libraries, constructed from the same fetal brain

mRNA. The protocol for library normalization is an improvement of the Sive and St. John protocol (Sive & St. John, 1988;). A short hybridization, corresponding to an estimated Cot of four, was carried out before addition of streptavidin to remove double-stranded DNA. Hybrid selection with alpha tubulin and beta actin was 5 performed, followed standard procedures. In each hybrid selection an average of two thousand colonies were examined.

TABLE II : Library Normalization Data

10	Normalized Library	Control Library	Improvement
$\alpha$ -tubulin (%)	0.1	0.9	9X
$\beta$ -actin (%)	0.1	0.7	7X

15

#### Pre-screening:

The number of false positive clones is reduced by performing a prescreen. URA counterselection is performed to remove the false positive signal from the DNA-binding domain alone. The DNA-binding domain library are transformed 20 separately into strain MaV203 and *ura*<sup>r</sup> colonies are selected on 5-FOA plates. All surviving colonies are used for the two-hybrid interaction screening procedure.

#### Interaction Screen:

Yeast mating (Bendixen *et al.*, *Nucleic Acids Res.* 22(9):1778-9. 1994) and 25 plasmid transformation followed by nutritional selection are used in the two-hybrid interaction screen. The DNA-Binding domain (DB) library is transformed into strain PJ69-2 (a mating type  $\alpha$  strain) and the Activation Domain (AD) library transformed into strain Y187 (a mating type  $\alpha$   $\sigma$ <sub>T</sub> $\rho$  $\alpha$  $\nu$ ). The  $\alpha$  and  $\alpha$  transformants are mated with subsequent nutritional selection. Plasmids that grow after nutritional selection 30 are isolated. Optimization of the mating/transformation step is critical because yeast cells, unlike *E. coli*, can acquire multiple plasmids following transformation. The

amount of DNA used in transformation is varied to alter the number of plasmids transformed into cells.

For an initial test, pilot scale experiments are performed using two different approaches. Tests with 10 known interacting pairs with various affinities are 5 conducted. The interactions among these 10 pairs are studied by 1) A matrix mating --- the interaction of every possible pair (100 pairs in combination is examined); 2) A "library vs. library" or batch screen --- the 10 clone pairs are mixed as two "mini-libraries" (one DB library and one AD library) followed by an interaction screen. The percentage of false positives and false negatives is determined for each 10 selection marker.

Following the initial tests, a small scale genome wide interaction screen is performed with a pair of two-hybrid FLEX<sup>TM</sup> cDNA libraries. The ADE selection marker was chosen. To tighten the screen an additional marker, the *E. coli lacZ* gene can be used. There are two possible alternatives to select for the clones. In one 15 scenario, the clones surviving nutritional selection are robotically picked to 96 well plates, followed by a liquid  $\beta$ -galactosidase assay with a chemiluminescent substrate (Campbell *et al.*, 1995). In the second scenario, a  $\beta$ -galactosidase filter assay is performed and the blue colonies are robotically distributed in 96 well plates.

## 20 Plasmid Retrieval

Isolation of plasmids from yeast is not trivial. The problem is particularly difficult when working with large plasmids (>6 kb). Low yields and genomic contamination are common. To rapidly isolate the plasmid, 1.5 ml of saturated yeast cells were spun down and lysed in 10  $\mu$ l of Lyticase for 60 min at 37° C, then 10  $\mu$ l 25 of 20% SDS was added with vigorous vortexing to help the cell lysis. The cells were put through one freeze/thaw cycle to ensure complete lysis. The whole cell lysate was passed through a spin column. The column beads of the high throughput spin column were purchased from Pharmacia Biotech (Sephacryl S-1000). The eluate from the spin column containing the purified DNA was collected for the 30 transformation into *E. coli* for amplification. After the plasmid is isolated from

-23-

yeast, the DNA is transformed back into *E.coli* for amplification. A multi-head electroporator from BTX, Genetronics, is used to increase the throughput. The two vector/three selectable markers system provides for efficient plasmid recovery.

## 5 Confirmation

Multiple *E. coli* transformants are picked, plasmid DNAs are isolated, and transformed back into yeast strains to confirm the interactions. Confirmation is necessary since yeast can carry multiple plasmids. It is worth noting that optimization of the plasmid transformation procedure may significantly lower the likelihood that a yeast cell carries more than one type of plasmid.

### Construction of Arrays and Identification of Interacting Clones by Hybridization Amplification of the DNAs

A library versus library two-hybrid screen was performed as described above.

15 The DNA-binding domain library was prescreened to remove clones that can activate the reporters in the absence of protein-protein interaction. Clones that passed the prescreen were mated with clones from an activation domain library. A portion of the mated cells were selected for those carrying protein-protein interactions.

Plasmids from a portion of the selected colonies were retrieved from yeast cells and 20 amplified in *E. coli* then extracted using standard molecular biology protocol.

One pair of interaction plasmids plus 10 known plasmids were spotted onto microarray slides in a duplicate fashion. Two independent clones from the 10 known genes were labeled with fluorescent CY3 or Cy5 for use as probes to determine whether the spotted plasmids can be correctly identified on microarray slides.

25 Approximately 1 µg of each plasmid DNA was resuspended in 5X SSC buffer for printing (spotting) onto the slides. The printing procedure was followed according to the manufacturer's instructions. Approximately 6ng of plasmid DNA was printed onto a single spot in duplicate.

-24-

Table VI

Locations (duplicate)	Plasmid Clone Name	Insert Description	Comment
A1, B1	YY367-1	B11 in pGBT9 vector	B11 is a novel gene previously identified as interacting with Snk (at A4 and B4)
5 A2, B2	F2	F2 in pGBT9	Interacts with F14 at A5 and B5
A3, B3	Alpha 4	Alpha 4 in pGBT9	Interacts with PP6 at A6 and B6
A4, B4	YY89-1	Snk in an activation domain vector (pGAD424)	Snk, a protein kinase, interacts with B11 at A1 and B1
A5, B5	F14	F14 in pGAD vector	Interacts with F2 at A2 and B2
A6, B6	PP6	PP6 in pGAD vector	Interacts with Alpha 1 At A3 and B3
10 A7, B7	YY313-9	B11 in pGAD vector	B11 is a novel gene previously identified as interacting with Snk (at A4 and B4)
A8, B8	TD-1	SV40 large T-antigen in pACT2	
A9, B9	B75	B75 in pGAD vector	
A10, B10	A18	A18 in pGAD vector	
C1, C3	2-hybrid clone 1	An unknown clone in DAN-binding domain vector	interacts with clone2 at C2 and C4
15 C2, C4	2-hybrid clone2	An unknown clone in activation domain vector	interacts with clone1 at C1 and C3

### Fluorescent Probe Synthesis

Genes B11 and Snk were excised from clones YY313-9 and YY8-11 respectively and the inserts were isolated from agarose gel by centrifugation.

Approximate 25ng of denatured DNAs were labeled by Cy3 and Cy5 dCTP

- 5 (purchased from Amersham Biotech) in a reaction containing random primer mixture and reaction buffer (both provided by High Prime DNA Labeling Kit from Boehringer Mannheim), 25 $\mu$ M 2'-deoxyadenosine-5' - triphosphate, 25 $\mu$ M 2'thymidine-5'-triphosphate, 25 $\mu$ M 2'-deoxyguanosine-5'-triphosphate, 5 $\mu$ M 2'-deoxycytidine-5'-triphosphate and 20 $\mu$ M Cy3 or Cy5 labeled 2'-deoxycytidine-5'-triphosphate and 4 U of Klenow polymerase. The reaction was incubated at 37° C for 45 min and stopped by incubating at 65° C for 10 min. The probes were purified by standard ethanol precipitation and resuspended in 10  $\mu$ l of hybridization buffer (6 X SSC, 5X Denhart's solution, 2% SDS, 0.1  $\mu$ g/ $\mu$ l of yeast tRNA).

### 15 Hybridization

- 2  $\mu$ l each of Cy3 probe and Cy5 probe were combined for hybridizing the DNA on each of glass slide. The slides were placed in slide chambers with a towel wet with 2 X SSC. They were brought up to 80 ° C for 10 min and then immediately put on ice to denature the DNA, hybridized at 62° C for 6 hours, then washed to remove 20 the unhybridized probes by 2X SSC, dried, and scanned by GenePix 4000 Microarray Scanner from Axon Instruments.

-26-

## Results

1. To evaluate the spotting procedure, a Cy5 or Cy3 labeled probe containing  
common vector sequences was hybridized to the DNA on glass slide. Figure 4  
5 showed that all DNAs were attached onto slide.

2. To localize the clone Snk

A Snk probe either labeled by Cy3 or Cy5 was hybridized to the slide. Figure  
10 5 shows Snk probe hybridizes both A4 and B4 DNAs which are the Snk  
clones.

3. To localize the clone B11:

15 A B11 probe either labeled by Cy3 or Cy5 was hybridized to the slide. Figure  
6 shows the B11 probe hybridizes locations A1, B1, A7, B7 (location 1  
represents B11 in pGBT9 and location 7 represents B11 in the pGAD vector).

Thus, a specific DNA probe can correctly identify homologous DNA on an array  
20 with little or no background. For example, if Snk is the polypeptide of interest, a  
labeled Snk polynucleotide is used to probe the interaction array. The hybridization  
identifies A4 and B4. From the linkage information shown in Table VI, the clone at  
A1 and B1 (B11) is identified as a Snk interacting clone. The linkage information is  
provided by the arrays of the present invention. This method can be used repetitively  
25 with newly identified interacting clones as the probes, to draw a protein interaction  
map and establish biological interaction pathways.

**Example 2: Construction of Two Hybrid Arrays****Plasmid vectors:**

A new vector is constructed to be used as the third plasmid partner. This vector carries URA3 marker, a yeast 2 $\mu$  origin of replication, a yeast nuclear localization signal, multiple cloning sites, ampicillin selection marker and Col E1 origin of replication. A yeast inducible promoter (Met25). A constitutive promoter (pADH) can also be used.

**Yeast Strains:**

10       A new  $\alpha$  mating type strain is constructed from Y187 the URA3 phenotype is reverted to ura3 by 5-Fluoroorotic Acid (5-FOA) counterselection. The desired genotype is (Mat $\alpha$ , ura3, his3, ade2, trp1, leu2, met, gal4 $\Delta$ , gal80 $\Delta$ , ura3::GAL1<sub>uas</sub>-GAL1<sub>TATA</sub>-lacZ). PJ69-2A (a mating type A strain) will be used in the mating assay as the second plasmid partner.

15

**Library construction:**

A series of brain cDNA libraries is constructed using technology described U.S. Patents 5,162,290, 5,643,766 and Serial No.: 09/062,452, the teachings of which are incorporated herein in their entirety. The bait library is cloned into the pGBT9 derived vector and the prey library is cloned into the PACT2-derived vector. Kinases are chosen for the third plasmid partner in 3PTH. Kinases are chosen to obtain sufficient activity. Kinases are selected based on the following criteria, either separately applied or applied in combination: (1) kinases that have been overexpressed in the host cell in the past; (2) kinases whose constitutive and/or inactive forms are available; (3) kinases which have homologous pathways in yeast (allowing activation in yeast by an endogenous activator if necessary); (4) kinases which are expressed in a tissue of interest (for example, brain tissue). The nucleic acid encoding the kinase or kinases are expressed under the control of an inducible promoter such as the MET25 inducible promoter.

-28-

The presence or absence of kinase activity under specified conditions is optimized using positive control pairs of proteins as shown in Table III. The first column represents the first hybrid protein, the second column represents the second hybrid protein, the third column represents the third plasmid partner (kinase) and the 5 fourth column represents the affinity of interaction after the hybrid protein is phosphorylated by the kinase listed in column 3.

Table III

	Hybrid 1	Hybrid 2	Kinase	Interaction Level <sup>1</sup>
10	CREB	CBP	PKA	increase
	IgE receptor	SH2-B	Syk or Lyn	increase
	RGSZ1	Gzalpha	PKC	increase
	HsEg5	dynactin (p150)	P34cdc2	increase
	NMDA receptor	calmodulin	PKC	decrease
15	Mu2	CTLA-4	PI3	decrease

1. of phosphorylated form

#### 3PTH Library Screening:

Both bait and prey fusion protein containing plasmids are transformed into one 20 haploid yeast strain (MAT<sub>a</sub>, for example) and the kinase containing plasmid(s) are transformed into the other haploid strain (MAT<sub>a</sub>). Figure 3 is a flow chart of the 3PTH system.

#### Screen for Interactions that Occur Only in the Unphosphorylated Form:

25 Both the pGBT9 based library and the PACT2 based library DNA are transformed into ura3 MAT<sub>a</sub> cells having the ade<sup>-</sup> genotype. White (ADE<sup>+</sup>) colonies are picked and arrayed onto 96 well plates by a robot. A control panel, including positive and negative controls are also placed onto each plate. The arrays of cells are grown and replica plated onto the desired number of plates (e.g. the number of

-29-

kinases to be screened plus one plate for a negative control of empty kinase vector).

The kinase vectors (carrying the URA3 marker) are transformed into MAT $\alpha$  cells.

The MAT $\alpha$  cells and MAT $\alpha$  cells, transformed as described above, are mated in batch fashion. White colonies are selected and the GBT9 and pGAD424 fusion 5 plasmids are recovered by Zeocin and Ampicillin selection, respectively, using standard plasmid isolation techniques. The desired clones have the following phenotypes:

Table IV

	Plasmid	Color in 3PTH Assay
10	GBT9 alone	red
	GAD424 alone	red
	GBT9 + GAD424	white
	GBT9 + GAD424 + kinase	red

15 DNA encoding proteins that interact with a polypeptide of interest only in the absence of phosphorylation are selected and isolated by probing the array of plasmids recovered above with DNA encoding the polypeptide of interest.

#### Screen for Interactions that Occur Only in the Presence of Phosphorylation

20 The initial screen for interacting proteins is performed as describe above except red transformed MAT $\alpha$  colonies are picked by the robot. The kinase transformed MAT $\alpha$  cells are mated to the selected, transformed MAT $\alpha$  cells in batch fashion. The HIS+ and ADE+ colonies are arrayed onto 96 well plates. The arrays are replicated onto two plates. On one plate, kinase expression is turned off by adding methanol to 25 turn off the MET2 promoter, or by adding 5-FOA to counter select the URA plasmid. The cells on the other plate are allowed to express the kinase. Colonies that are white on the kinase+ plate and red on the kinase- plate are selected. Plasmids are recovered as described above. The desired clones have the following phenotypes:

-30-

Table V

Plasmid	Color in 3PTH Assay
GBT9 alone	red
GAD424 alone	red
5 GBT9 + GAD424	red
Kinase + GBT9	red
Kinase + GAD424	red
GBT + GAD424 + kinase	white

10 DNA encoding proteins that interact with a polypeptide of interest only in the presence of phosphorylation are selected and isolated by probing the array of plasmids selected above with DNA encoding the polypeptide of interest.

#### EQUIVALENTS

15 Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

## CLAIMS

What is claimed is:

- 5 1. A method of identifying polynucleic acids encoding at least one polypeptide capable of interacting, *in vivo* with a polypeptide of interest comprising:
  - a) contacting at least one array of plasmids with a probe, wherein:
    - i) said probe encodes the polypeptide of interest or fragment thereof, wherein said probe hybridizes to complementary sequence, if present, within any of the plasmids, and wherein:
    - 10 ii) said array comprises two or more plasmid partners, wherein a first plasmid partner comprises a first library fused to a first nucleic acid sequence encoding a first half of a selection pair and a second plasmid partner comprises the same or a second library fused to a second nucleic acid sequence encoding a second half of a selection pair and wherein the plasmid partners are selected to be in the array by their ability to, in concert, 15 activate the selection pair in a host cell, and
  - b) identifying the partner or partners to said hybridized plasmid, 20 wherein said partner or partners encode a polypeptide capable of interacting, *in vivo* with the polypeptide of interest.
2. The method of Claim 1, wherein the selection pair comprises a DNA binding domain and a transcriptional activation domain.
- 25 3. The method of Claim 2, wherein the DNA binding domain sequence is selected from the group consisting of: GAL., lexA, GCN4 and ADR1.
4. The method of any one of Claims 2 or 3, wherein the transcription activation domain sequence is selected from the group consisting of: GAL., GCN4, 30 ADR1 and herpes simplex VP16.

-32-

5. The method of any one of Claims 1 through 4, wherein the first library is normalized.
6. The method of any one of Claims 1 through 5, wherein the second library is normalized.
7. The method of any one of Claims 1 through 6, wherein the library of the first plasmid partner is fused at its 5' end to the first nucleic acid sequence.
- 10 8. The method of any one of Claims 1 through 6, wherein the library of the first plasmid partner is fused at its 3' end to the first nucleic acid sequence.
9. The method of any one of Claims 1 through 8, wherein the library of the second plasmid partner is fused at its 3' end to the second nucleic acid sequence.
- 15 10. The method of any one of Claims 1 through 8, wherein the library of the second plasmid partner is fused at its 5' end to the second nucleic acid sequence.
- 20 11. The method of any one of Claims 1 through 10, wherein the plasmid partners are in separate linked arrays.
- 25 12. The method of any one of Claims 1 through 10, wherein the plasmid partners are together in the same array.
13. The method of any one of Claims 1 through 12, wherein a) further comprises a third plasmid comprising a sequence encoding at least one post-translational modifying enzyme.
- 30 14. The method of Claim 13, wherein the post-translational modifying enzyme is under the control of an inducible promoter system.

15. The method of Claims 13 or 14, wherein the post-translational modifying enzyme is selected from the group consisting of kinases, phosphatases, glycosylation enzymes and endoproteases.
- 5 16. The array of any one of Claims 1 through 15, wherein the array comprises at least one set of plasmids comprising two or more plasmid partners, wherein a first plasmid partner comprises a first library fused a first nucleic acid sequence encoding a first half of a selection pair and a second plasmid partner comprising the same or a second library fused to a second nucleic acid sequence encoding a second half of a selection pair, and wherein the plasmid partners are selected to be in the array by their ability to, in concert, activate the selection pair in a host cell.
- 10 17. A method of identifying polynucleic acids encoding at least one polypeptide capable of interacting, *in vivo*, with a polypeptide of interest, wherein the interaction is affected by post-translational modification, comprising:
  - a) contacting at least one array with a probe, wherein:
    - i) said probe encodes the polypeptide of interest or fragment thereof, wherein said probe hybridizes to complementary sequence, if present, within any of the plasmids, and wherein:
    - 20 ii) said array comprises and two or more plasmid partners, wherein a first plasmid partner comprises a first library fused to a first nucleic acid sequence encoding a first half of a selection pair, a second plasmid partner comprising the first or a second library fused to a nucleic acid sequence encoding a second half of a selection pair and a third plasmid partner comprising a polynucleic acid sequence encoding at least one post-translational modifying enzyme, wherein the first and second plasmid partners are selected by their ability to, in concert activate the selection pair in a host cell,
  - 25 b) identifying the partner or partners to said hybridized plasmid,
- 30

-34-

wherein said partner or partners encode a polypeptide capable of interacting with the polypeptide of interest.

18. The method of Claim 17, wherein the selection pair comprises a DNA binding domain and a transcriptional activation domain.  
5
19. The method of Claim 18, wherein the DNA binding protein domain sequence is selected from the group consisting of: GAL., lexA, GCN4 and ADR1.
- 10 20. The method of any one of Claims 18 or 19, wherein the transcription activation domain sequence is selected from the group consisting of: GAL., GCN4, ADR1 and herpes simplex VP16.
21. The method of any one of Claim 17 through 20, wherein the first library is  
15 normalized.
22. The method of any one of Claims 17 through 21, wherein the second library is normalized.
- 20 23. The method of any one of Claims 17 through 22, wherein the library of the first plasmid partner is fused at its 5' end to the first nucleic acid sequence.
24. The method of any one of Claims 17 through 22, wherein the library of the first plasmid partner is fused at its 3' end to the first nucleic acid sequence.  
25
25. The method of any one of Claims 17 through 24, wherein the library of the second plasmid partner is fused at its 3' end to the second nucleic acid sequence.
- 30 26. The method of any one of Claims 17 through 24, wherein the library of the second plasmid partner is fused at its 5' end to the second nucleic acid sequence.

27. The method of any one of Claims 17 through 26, wherein the plasmid partners are in separate linked arrays.
28. The method of any one of Claims 17 through 26, wherein the plasmid partners  
5 are together in the same array.
29. The method of any one of Claims 17 through 28, wherein the post-translational modifying enzyme is selected from the group consisting of kinases, phosphatases, glycosylation enzymes and endoproteases.  
10
30. The method of any one of Claims 17 through 29, wherein the post-translational modifying enzyme is under the control of an inducible promoter system.  
15
31. The method of Claim 30, wherein the inducible transcriptional system is selected from the list consisting of: MET25, heat shock, GAL and tetracycline sensitive promoters.  
20
32. The method of any one of Claims 17 through 31, wherein the interaction is inhibited by the post-translational modification.  
25
33. The array of any one of Claims 17 through 32, wherein the array comprises at least one set of plasmids comprising two or more plasmid partners, wherein a first plasmid partner comprises a first library fused to a first nucleic acid sequence encoding a first half of a selection pair and a second plasmid partner comprising the same or a second library fused to a second nucleic acid sequence encoding a second half of a selection pair, and wherein the plasmid partners are selected to be in the array by their ability to, in concert, activate the selection pair in a host cell.  
30
34. A composition comprising at least one array of plasmids comprising two or more plasmid partners, wherein a first plasmid partner comprises a first library fused to a first nucleic acid sequence encoding a first half of a selection pair

and a second plasmid partner comprising the same or a second library fused to a second nucleic acid sequence encoding a second half of a selection pair, and wherein the plasmid partners are selected to be in the array by their ability to, in concert, activate the selection pair in a host cell.

5

35. A composition comprising an array of plasmids comprising two or more plasmid partners wherein a first plasmid partner comprises a first library fused to a nucleic acid encoding a DNA binding domain, a second plasmid partner comprises the first or a second library fused to a nucleic acid sequence encoding a transcriptional activation domain, wherein the first and second plasmid partners are selected to be in the array by their ability to, in concert and in the absence of expression of said post-translational modifying enzyme, activate transcription of one or more marker genes in a host cell, wherein the post-translational modifying enzyme is encoded by a third plasmid partner in the host cell.
- 10  
15
36. A composition comprising an array of plasmids comprising two or more plasmid partners wherein a first plasmid partner comprises a first library fused to a nucleic acid encoding a DNA binding domain, a second plasmid partner comprises the first or a second library fused to a nucleic acid sequence encoding a transcriptional activation domain, wherein the first and second plasmid partners are selected to be in the array by their ability to, in concert and in the presence of expression of said post-translational modifying enzyme, activate transcription of one or more marker genes in a host cell, wherein the post-translational modifying enzyme is encoded by a third plasmid partner in the host cell.
- 20  
25
37. The method of any one of Claims 34 through 36, wherein the selection pair comprises a DNA binding domain and a transcriptional activation domain.

30

38. The composition of Claims 37, wherein the DNA binding protein domain sequence is selected from the group consisting of: GAL., lexA, GCN4 and ADR1.
- 5 39. The composition of Claims 37 or 38, wherein the transcription activation domain sequence is selected from the group consisting of: GAL., GCN4, ADR1 and herpes simplex VP16.
- 10 40. The composition of any one of Claims 34 through 39, wherein the first library is normalized.
41. The composition of any one of Claims 34 through 40, wherein the second library is normalized.
- 15 42. The composition of any one of Claims 34 through 41, wherein the library of the first plasmid partner is fused at its 5' end to the first nucleic acid sequence.
43. The composition of any one of Claims 34 through 41, wherein the library of the first plasmid partner is fused at its 3' end to the first nucleic acid sequence.
- 20 44. The composition of any one of Claims 34 through 42, wherein the library of the second plasmid partner is fused at its 3' end to the second nucleic acid sequence.
- 25 45. The composition of any one of Claims 34 through 42, wherein the library of the second plasmid partner is fused at its 5' end to the second nucleic sequence.
46. The composition of any one of Claims 34 through 45, wherein the plasmid partners are in separate linked arrays.
- 30 47. The composition of any one of Claims 34 through 45, wherein the plasmid partners are together in the same array.

-38-

48. The composition of any one of Claims 35 through 47, wherein the post-translational modifying enzyme is selected from the group consisting of kinases, phosphatases, glycosylation enzymes and endoproteases.
- 5 49. The composition of any one of Claims 35 through 48, wherein the post-translational modifying enzyme is under the control of an inducible promoter.
50. The composition of Claim 49, wherein the inducible promoter is selected from the list consisting of: MET25, heat shock, GAL and tetracycline sensitive  
10 promoters.
51. A kit comprising at least one array of plasmids comprising two or more plasmid partners, wherein a first plasmid partner comprises a first library fused to a first nucleic acid sequence encoding a first half of a selection pair and a second plasmid partner comprising the same or a second library fused to a second nucleic acid sequence encoding a second half of a selection pair, and wherein the plasmid partners are selected to be in the array by their ability to, in concert, activate the selection pair in a host cell, buffers for hybridizing polynucleic acids of interest to said array, and instructions for hybridization.  
15
- 20 52. A method of generating an array of plasmids comprising:
  - a) conducting a two-hybrid screen, wherein a bait plasmid comprises a cDNA library and a prey plasmid comprises the same or a second cDNA library
  - b) selecting positive two-hybrid clones and
  - c) immobilizing the bait and prey plasmids from said positive clones on a solid support at known locations,  
thereby generating an array of plasmids.  
25




FIG. 1

BEST AVAILABLE COPY








Figure 2




BEST AVAILABLE COPY

Figure 3




BEST AVAILABLE COPY

Figure 4



C    B    A

Cy 3



C    B    A

Cy 5

Figure 5

BEST AVAILABLE COPY




Figure 6

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 August 2000 (10.08.2000)

PCT

(10) International Publication Number  
**WO 00/46406 A3**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68, C12N 15/10

(21) International Application Number: PCT/US00/02974

(22) International Filing Date: 4 February 2000 (04.02.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/118,901 5 February 1999 (05.02.1999) US

(71) Applicant (for all designated States except US): ALPHA-GENE, INC. [US/US]; 260 West Cummings, Woburn, MA 01801 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YUAN, Olive, Yi-Lu [US/US]; 292 Mystic Street, Arlington, MA 02474 (US). VALENZUELA, Dario [CL/US]; 347 Lowell Street, 3rd Floor, Sommerville, MA 02145 (US). RAPEJKO, Peter [US/US]; 63 Old Grafton Road, Upton, MA 01568 (US). HOFFMANN, Heidi [US/US]; 90 Houghton's Mall Road, Lunenburg, MA 01462 (US). HIGGINS, Kara, Ann [US/US]; 13 Woodbury Road, Billerica, MA 01821 (US).

(74) Agents: HOGLE, Doreen, M. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

(88) Date of publication of the international search report: 12 April 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A3

WO 00/46406

(54) Title: ARRAYS FOR INVESTIGATING PROTEIN PROTEIN INTERACTIONS

(57) Abstract: A method is provided for the rapid identification of protein-protein interaction networks within a cell, tissue, or whole genome. The introduction of a multi-bait approach is a distinguishing feature of the technology. In this method a pair of two-hybrid cDNA libraries, each one carrying the complement of genes from the tissue under study, are combined for an interaction screen. A large number of yeast colonies, each identifying a protein interaction pair, are picked and distributed in single wells, providing an arrayed archive of protein-protein interactions. The archive also serves as a source of plasmids to construct arrayed replicas containing DNA of the interacting plasmid pairs. Hybridization of a given cDNA to the arrayed replicas identifies the corresponding interacting clones. Protein interaction networks are constructed by iteration of the hybridization with newly identified interacting clones.

# INTERNATIONAL SEARCH REPORT

Intern. Application No  
PCT/US 00/02974

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C12Q1/68 C12N15/10

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12Q C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FROMONT-RACINE M ET AL: "TOWARD A FUNCTIONAL ANALYSIS OF THE YEAST GENOME THROUGH EXHAUSTIVE TWO-HYBRID SCREENS" NATURE GENETICS, US, NEW YORK, NY, vol. 16, 1 July 1997 (1997-07-01), pages 277-282, XP000770741 ISSN: 1061-4036 the whole document ---	1-52
Y	FIELDS S ET AL: "THE TWO-HYBRID SYSTEM: AN ASSAY FOR PROTEIN-PROTEIN INTERACTIONS" TRENDS IN GENETICS, NL, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 10, no. 8, 1 August 1994 (1994-08-01), pages 286-292, XP000647708 ISSN: 0168-9525 the whole document ---	1-52
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

24 November 2000

Date of mailing of the international search report

04/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Knehr, M

## INTERNATIONAL SEARCH REPORT

Intern. .... Application No

PCT/US 00/02974

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WODICKA ET AL: "GENOME-WIDE EXPRESSION MONITORING IN SACCHAROMYCES CEREVISIAE" NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 15, December 1997 (1997-12), pages 1359-1367, XP002100297 ISSN: 1087-0156 the whole document ---	
A	LECRENIER ET AL: "TWO-HYBRID SYSTEMATIC SCREENING OF THE YEAST PROTEOME" BIOESSAYS, GB, CAMBRIDGE, vol. 20, no. 1, January 1998 (1998-01), pages 1-5-6, XP002100659 ISSN: 0265-9247 the whole document ---	
A	R J CHO ET AL: "Parallel analysis of genetic selections using whole genome oligonucleotide arrays" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, US, vol. 95, no. 7, 31 March 1998 (1998-03-31), pages 3752-3757, XP002146711 ISSN: 0027-8424 the whole document ---	
A	JAMES P ET AL: "Genomic libraries and a host strain designed for highly efficient two-hybrid selection in yeast" STN MEDLINE, XP002130070 the whole document ---	
A	DE 196 28 894 A (HAGENMAIER HANS PAUL) 22 January 1998 (1998-01-22) the whole document -----	

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Intern ... Application No  
PCT/US 00/02974

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 19628894 A	22-01-1998	WO 9803676 A	29-01-1998

## CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 August 2000 (10.08.2000)

PCT

(10) International Publication Number  
**WO 00/46406 A3**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68,  
C12N 15/10

(21) International Application Number: PCT/US00/02974

(22) International Filing Date: 4 February 2000 (04.02.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/118,901 5 February 1999 (05.02.1999) US

(71) Applicant (for all designated States except US): ALPHA-GENE, INC. [US/US]; 260 West Cummings, Woburn, MA 01801 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YUAN, Olive, Yi-Lu [US/US]; 292 Mystic Street, Arlington, MA 02474 (US). VALENZUELA, Dario [CL/US]; 347 Lowell Street, 3rd Floor, Sommerville, MA 02145 (US). RAPEJKO, Peter [US/US]; 63 Old Grafton Road, Upton, MA 01568 (US). HOFFMANN, Heidi [US/US]; 90 Houghton's Mall Road, Lunenburg, MA 01462 (US). HIGGINS, Kara, Ann [US/US]; 13 Woodbury Road, Billerica, MA 01821 (US).

(74) Agents: HOGLE, Doreen, M. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
12 April 2001

(48) Date of publication of this corrected version:  
7 September 2001

(15) Information about Correction:  
see PCT Gazette No. 36/2001 of 7 September 2001, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

A3

WO 00/46406

(54) Title: ARRAYS FOR INVESTIGATING PROTEIN PROTEIN INTERACTIONS

(57) Abstract: A method is provided for the rapid identification of protein-protein interaction networks within a cell, tissue, or whole genome. The introduction of a multi-bait approach is a distinguishing feature of the technology. In this method a pair of two-hybrid cDNA libraries, each one carrying the complement of genes from the tissue under study, are combined for an interaction screen. A large number of yeast colonies, each identifying a protein interaction pair, are picked and distributed in single wells, providing an arrayed archive of protein-protein interactions. The archive also serves as a source of plasmids to construct arrayed replicas containing DNA of the interacting plasmid pairs. Hybridization of a given cDNA to the arrayed replicas identifies the corresponding interacting clones. Protein interaction networks are constructed by iteration of the hybridization with newly identified interacting clones.

## PROTEOMIC INTERACTION ARRAYS

### RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/118,901, filed February 5, 1999, the teachings of which are incorporated herein by reference in their entirety.

### BACKGROUND OF THE INVENTION

The identification of new pathways involving protein-protein interaction in disease states has a high commercial value because of their potential to identify therapeutic targets. A variety of procedures have been developed to identify interactions between proteins. Three common biochemical methods to screen for interacting proteins are, co-immunoprecipitation, affinity chromatography, and expression library screening. Coimmunoprecipitation is one of the most common biochemical methods to search for interacting proteins. For example, the well-known interaction between retinoblastoma protein (p110<sup>RB</sup>) and adenoviral protein E1A was obtained using this approach (Whyte *et al.*, *Nature* 334:124-129 (1988)). Affinity chromatography typically involves a bait protein linked to beads. Proteins that interact with a bait protein bind the bait and are eluted after washing the column. A typical application is to use glutathione-S-transferase protein (GST) fused to a polypeptide of interest as the bait protein. Expression library screening involves screening the library using a labeled bait protein as a probe. Expression library screening has been successful in identifying genes encoding proteins that interact with calmodulin, jun, myc, the EGF receptor and the retinoblastoma protein. Although these methods have generated many significant results, they are all *in vitro* methods and are generally difficult to modify for high throughput. Furthermore, once the interacting proteins are identified, the cloning of its

-2-

corresponding gene could be very challenging and not easily engineered for high throughput analysis on discovery.

An *in vivo* genetic approach to detect protein-protein interactions is the yeast two-hybrid system. The two-hybrid system is typically applied to detect the 5 interaction between two proteins or to isolate interacting proteins from a library using a specific bait.

The two-hybrid system permits an *in vivo* identification of the interacting proteins. Hence, the conformation of the target protein in yeast cells is closer to the native form than most of the *in vitro* conditions that are available, and reasonably it 10 is therefore more likely to yield physiologically significant proteins. It is likely to be more sensitive for detection of protein-protein interaction than many other methods, such as probing an expression library with a labeled protein or co-immunoprecipitation, based on the parallel comparisons (Li *et al.*, *FASEB J.* 7:957-963 (1993)). This sensitivity allows the isolation of weaker or transiently interacting 15 proteins. Numerous protein interactions have been successfully detected by using the two-hybrid system, including cell cycle factors, signal transduction factors, proteins involved in apoptosis and DNA repair.

The use of the two-hybrid approach to determine protein-protein interaction rapidly and on a large scale has certain obstacles. Modification for high throughput 20 analysis of protein-protein interaction or high throughput identification of novel interacting proteins requires a tremendous amount of labor intensive subcloning of gene sequences of interest and sequencing of newly discovered candidate genes from libraries, making high throughput two-hybrid approaches time consuming and expensive. Traditionally, two-hybrid screens are performed using a single bait 25 protein, screening nucleic acids that encode potentially interacting proteins, retrieving the clones encoding the interacting proteins, sequencing these clones, and storing the sequence information *in silico*. The sequencing cost is extremely high when a genome-wide two-hybrid screen performed.

Furthermore, it has been estimated that the human genome encodes 100,000 30 proteins with potentially 50 billion different protein-protein interactions. However,

-3-

not all of these interactions are expected to be involved in pathways that are either involved in disease or development or are suitable drug targets. Thus, analysis of all two-hybrid interacting pairs involves considerable time, effort and expense for interactions that may have little or no commercial or research value.

5 Another limitation of the traditional two-hybrid approach has been the inability to reconstitute interactions mediated by several components or interactions that are dependent on specific post-translational modifications. Several assays have been described to overcome this barrier, including co-expression of a protein tyrosine kinase as a modifying enzyme to assess the interactions between  
10 phosphoproteins. However, these studies typically focus on a single bait protein and the interactions in the presence of the third protein, either as a modifier or stabilizer.

Further, limitations of the two-hybrid approach are the presence of false positives and false negatives. Although improvements have been implemented to reduce the number of false positives, the problem still exists. From the  
15 bacteriophage T7 protein linkage mapping project, it was found that the large majority of false positives appear to be due to transcriptional activation from the DNA binding domain clones in the absence of protein-protein interaction. That is to say, the DNA-binding domain hybrid (BD-X) activates the reporter gene by itself. In addition, false positives can result from the non-specific interaction via short  
20 stretches of residues.

## SUMMARY OF THE INVENTION

The present invention is drawn to a method of selecting nucleic acids encoding polypeptides, wherein the polypeptides are capable of interacting, *in vivo*  
25 (e.g., in a living cell) with a polypeptide of interest. The method comprises providing or generating an array of plasmid partners and probing the array with nucleic acid encoding a polypeptide of interest. Polynucleotides encoding a polypeptide that interacts with the polypeptide of interest are identified by contacting the array with polynucleotide probe encoding all or a portion of said  
30 polypeptide of interest under conditions where the probe detectably hybridizes to

complementary sequence, if present, within any of the plasmids of the array.

Plasmid partner or partners of the hybridized plasmid are identified and optionally isolated, wherein said partner or partners encode a polypeptide capable of interacting, under physiological conditions, with the polypeptide of interest.

5       The plasmid partners comprise two or more plasmids wherein each plasmid comprises a polynucleotide sequence encoding a polypeptide fused or linked to nucleic acid sequence encoding a DNA binding protein domain or a transcriptional activation domain. The plasmid partners are selected to be in the array by their ability to, in concert, produce a detectable biochemical readout, e.g., transcription of  
10 one or more marker genes in a host cell.

The present invention is drawn to a method of isolating polynucleic acids encoding at least one polypeptide capable of interacting, *in vivo* with a polypeptide of interest comprising:

a)       contacting at least one array of plasmids with a probe, wherein:

15           i)       said probe encodes the polypeptide of interest or fragment thereof, wherein said probe hybridizes to complementary sequence, if present, within any of the plasmids, and wherein:  
                ii)      said array comprises two or more plasmid partners, wherein a first plasmid partner comprises a first library fused to a first nucleic acid sequence encoding a first half of a selection pair and a second plasmid partner comprises the same or a second library fused to a second nucleic acid sequence encoding a second half of a selection pair and wherein the plasmid partners are selected to be in the array by their ability to, in  
20           concert, activate the selection pair in a host cell, and

25           b)       identifying the partner or partners to said hybridized plasmid, wherein said partner or partners encode a polypeptide capable of interacting, *in vivo* with the polypeptide of interest.

The present invention is drawn to a method of generating an array of

30 plasmids comprising:

-5-

- a) conducting a two-hybrid screen, wherein bait plasmids comprise a cDNA library and a prey plasmids comprise the same or a second cDNA library;
- b) selecting positive two-hybrid clones and
- 5 c) immobilizing the bait and prey plasmids from said positive clones on a solid support at known locations, thereby generating an array of plasmids.

In another embodiment of the present invention, a method is provided for selecting polypeptides capable of interacting *in vivo* with a polypeptide of interest, 10 wherein the interaction is dependent upon post-translational modification. The method comprises providing or generating arrayed sets of plasmids comprising three or more plasmid partners, wherein a first plasmid partner comprises a library of sequences encoding polypeptides fused or linked to nucleic acid sequence encoding a DNA binding domain and wherein a second plasmid partner comprising the same 15 or a second library fused or linked to nucleic acid encoding a transcriptional activation domain and wherein a third plasmid partner comprises at least one post-translational modifying enzyme. The expression of said enzyme is optionally under the control of an inducible transcription system. The first and second plasmid partners are selected by their ability, in concert, and in the presence of the expressed 20 post-translational modifying enzyme, activate transcription of one or more marker genes in a host cell. Polypeptides that interact with the polypeptide of interest are selected by contacting nucleic acid encoding the polypeptide of interest to the array, under conditions where the nucleic acid detectably hybridizes to complementary sequence, if present, within any of plasmids. Plasmid partner or partners of the 25 hybridized plasmid are identified and optionally isolated, wherein said partner or partners encode a polypeptide capable of interacting, *in vivo* and in a post-translational modification dependent manner, with the polypeptide of interest.

In another embodiment of the present invention, a method is provided for selecting polypeptides capable of interacting under physiological conditions, with a 30 polypeptide of interest, wherein the interaction is inhibited by post-translational

modification. The method comprises providing or generating arrayed sets of plasmids comprising three or more plasmid partners, wherein a first and second plasmid partner as described above and a third plasmid partner comprising at least one post-translational modifying enzyme. The expression of said enzyme is 5 optionally under the control of an inducible transcription system. The first and second plasmid partners are selected by their ability to, in concert and in the absence of the post-translational modifying enzyme, activate transcription of one or more marker genes in a host cell. The array is probed with a polynucleotide encoding polypeptide of interest as described above.

10 The present invention provides a powerful tool to generate complete linkage map of proteins encoded by the cDNA library used to create the plasmid partner array. This information can be stored in the form of a DNA chip, avoiding the high cost of sequencing all clones. The method of the present invention is particularly suitable for high throughput operation. The archive of arrays of the present 15 invention allows identification and retrieval of the X, Y, or both sequences using standard hybridization techniques. A sequence of interest is used to probe the arrays of the linkage map by hybridization. A positive signal reveals both the sequence homologous to the probe as well as the partner plasmid. By using the linkage map of the present invention, one can probe the map with a sequence encoding a protein 20 of interest, which hybridizes selectively to complementary sequences, when present, in the X or Y inserts and find a corresponding plasmid that encodes a protein that interacts with the protein of interest. For example, if the sequence encoding the protein of interest hybridizes to X<sub>1</sub>, then the location of Y<sub>1</sub> in the array will be provided by the linkage map. The X<sub>1</sub> or Y<sub>1</sub>, sequence provided by the map can be 25 used to probe for other interacting proteins.

In the method of the present invention, any pair of DNA-binding domains and activation domains can be used. Furthermore, any site-specific transcription factor that has separable DNA binding domain and activation domain can be used. Other methods to identify protein-protein interactions in the two hybrid-derived 30 system include other reconstitutive methods whereby two domains that together

produce a biochemical readout can be physically separated such that the reassociation of the separated domains via protein X and Y interaction reconstitutes the biochemical readout; for example, as reviewed by Mendelsohn and Brent (the teachings of which are incorporated by reference herein in their entirety). The 5 membrane binding and catalytic domains of guanine exchange factor can be used (Mendelsohn and Brent, *Science* 284:1948-1950 (1999)). These separated domains are referred to herein as a first and second half of a selection pair, respectively.

The present invention is advantageous over other biochemical methods for a number of reasons. The present invention uses arrays to store all protein-protein 10 interaction information identified using two-hybrid screening without performing a large amount of subcloning or sequencing. Instead, the positively interacting pairs are identified using probes selected by the user to hybridize the array and identify all locations of the array that contain DNA encoding the protein of interest and partner 15 plasmids in the same or linked array that encode proteins that interact with said protein of interest. Therefore, the present invention significantly reduces the cost of mapping protein interactions on a cellular, tissue or genome wide scale. Moreover, the arrays of the present invention provide an archive in which a user can obtain the 20 interaction partners rapidly by DNA hybridization; a much faster and simpler technique than yeast two-hybrid screen. A database of interacting partners can be produced by storing the identity of partner pairs identified by hybridization in 25 computer table. The modification of using different selection markers on bait and prey vectors in the two-hybrid system simplifies the plasmid DNA recovery process and speeds up the entire two-hybrid screening procedure. In addition, the process of generating the array, probing the array and identifying plasmids encoding interacting pairs of proteins can be automated.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram of the generation of Proteomic Interaction Arrays.

Figure 2 is a diagram of two plasmids for use in the two-hybrid screen of the present invention.

Figure 3 is a schematic diagram of the generation of Proteomic Interaction Arrays using three protein, two-hybrid (3PTH).

5       Figure 4 shows the hybridization of vector sequences to the test array of Example 1.

Figure 5 shows the hybridization of an Snk probe to the test array of Example 1.

10     Figure 6 shows the hybridization of an B11 probe to the test array of Example 1.

#### DETAILED DESCRIPTION OF THE INVENTION

The human genome sequencing project has had a revolutionary effect on biological research. The decoding of all genes brings the blueprint of life to 15 scientists, while the function of genes still remains a mystery. Since virtually all cellular processes are controlled by proteins, including disease processes and developmental processes, knowledge of how proteins interact is necessary to understand these processes.

The present invention relates to a novel high throughput approach to two- 20 hybrid analysis. The yeast two-hybrid system is a genetic approach which allows one to detect protein-protein interaction *in vivo* through the reconstitution of the activity of a transcriptional activator, such as GAL4, in yeast *Saccharomyces cerevisiae*. The key of the two-hybrid system is the finding that site-specific transcription factors are often modular, comprised of separable DNA-binding 25 domains (BDs) that bind to a specific promoter sequence, and activation domains (ADs) that direct the RNA polymerase II complex to transcribe the gene downstream of the DNA binding site. This phenomenon is exploited by fusing separate binding and activation domains to a pair of interacting proteins, X and Y, to create two hybrid proteins, BD-X and AD-Y. If the X and Y proteins interact, co-

expression of two hybrids in a yeast cell leads to expression of a reporter gene containing the cognate BD-binding site. This approach can be also used to isolate cDNAs encoding partners for a protein of interest from an AD-Y library.

The present invention is drawn to a genome-wide scale two-hybrid screen.

5 The method of the present invention involves a rapid plasmid retrieval system to recover plasmids from two-hybrid positive cells, an array system to store the interaction information using suitable substrates such as filter membranes or microarrays (eg. on glass slides), and a hybridization method to identify nucleic acid encoding proteins that interact with a polypeptide of interest. The present invention  
10 also relates to cDNA libraries constructed in suitable two-hybrid plasmids, such as the two plasmids shown in Figure 2.

The present invention is drawn to a method to quickly identify DNA encoding proteins which interact with a protein of interest, by probing the arrays of the present invention with nucleic acid encoding the protein of interest. The method  
15 involves construction of an array of protein-protein interactions represented by plasmid pairs, wherein the plasmid pairs have been selected from a genome-wide scale two-hybrid screen. The collection of plasmid pairs is referred to herein as an “interaction library” or array. In this embodiment, the first and second plasmid pairs are generated using the cDNA library from a cell line or tissue of interest. In  
20 another embodiment, the array represents the entire complement of protein-protein interactions of an organism. The present invention can also be applied to other screens, such as yeast three-hybrid, one-hybrid, and mammalian two-hybrid screen.

In the method of the present invention, positive yeast hybrids from the two-hybrid assay are selected and distributed in an array, such as a two dimensional array. The clones are also stored for future access. Each yeast hybrid is a clone containing at least two plasmids. To identify nucleic acid encoding polypeptides that interact with a polypeptide of interest, the plasmids from the yeast clone array are transferred to a solid support for hybridization screening. The plasmid array is probed with a nucleic acid selected by a user. In one embodiment, the nucleic acid  
30 encodes a protein of interest. The array is contacted with the probe under suitable

-10-

hybridization conditions. The wells or array locations containing nucleic acid homologous with specific probe are identified by hybridization with the probe. Vectors or plasmids encoding interacting partner(s) of the protein of interest are also identified. After identification of the vectors encoding interacting partners, the 5 process can be repeated with the newly identified polynucleic acid molecules to reveal polynucleic acids encoding proteins that interact with the previously identified interacting partners. Thus, the method and arrays of the present invention provide networks of interaction pathways within a cell.

The skilled artisan will recognize that factors commonly used to impose or 10 control stringency of hybridization include formamide concentration (or other chemical denaturant reagent), salt concentration (i.e., ionic strength), hybridization temperature, detergent concentration, pH and the presence or absence of chaotropes. Optimal stringency for a probe/target combination is often found by the well known technique of fixing several of the aforementioned stringency factors and then 15 determining the effect of varying a single stringency factor. Optimal stringency for hybridizing the user defined probe to the array may be experimentally determined by examining variations of each stringency factor until the desired degree of discrimination between specific and non-specific sequences has been achieved. The level of stringency will increase or decrease depending on whether the target and 20 variable regions are complementary or substantially complementary.

A general description of stringent hybridization conditions is provided in Ausubel, F.M., *et al.*, *Current Protocols in Molecular Biology*, Greene Publishing Assoc. and Wiley-Interscience 1989, the teachings of which are incorporated herein by reference. The influence of factors such as probe length, base composition, 25 percent mismatch between the hybridizing sequences, temperature and ionic strength on the stability of nucleic acid hybrids is well known in the art. Thus, stringency conditions sufficient to allow the user defined probes to hybridize with specificity to a homologous nucleic acid sequence, if present, in the array can be determined empirically. The probe need not hybridize to the nucleic acid sequence of interest

with exact complementarity, so long as the target nucleic acid sequence of interest is identical or nearly identical to the probe, e.g., a homologue or variant.

Conditions for stringency are also described in: Secreted Proteins and Polynucleotides Encoding Them, (Jacobs *et al.*, WO 98/40404), the teachings of which are incorporated herein by reference. In particular, examples of highly stringent, stringent, reduced and least stringent conditions are provided in WO 98/40404 in the Table on page 36. In one embodiment of the present invention, highly stringent conditions are those that are at least as stringent as, for example, 1x SSC at 65°C, or 1x SSC and 50% formamide at 42°C. Moderate stringency conditions are those that are at least as stringent as 4x SSC at 65°C, or 4x SSC and 50% formamide at 42°C. Reduced stringency conditions are those that are at least as stringent as 4x SSC at 50°C, or 6x SSC and 50% formamide at 40°C.

The present invention expedites the process of discovering novel interaction pathways while minimizing the need for subcloning or sequencing polynucleotides that do not encode proteins that interact with a polypeptide of interest.

Also provided by the present invention are two-hybrid plasmids, one containing the DNA-binding domain (first plasmid) and the other containing the activation domain (second plasmid). These two plasmids use two different *E. coli* selection markers. Useful selection markers for the present invention include for example, genes encoding ampicillin, kanamycin, chloramphenicol, tetracycline, Zeocine and trimethoprim resistance. In one embodiment, three selection markers can be used. For example, a unique selectable marker can be present on each of the plasmids, such as ampicillin on plasmid one and kanamycin on plasmid two, and a common selectable marker present on both plasmids. In another embodiment, one marker can be used a common marker present on both plasmids. The markers allow the isolation of the plasmids using techniques well known in the art. For example, the plasmids isolated from the two hybrid clone can be transformed into *E. coli* which are grown in the presence of the appropriate antibiotic. Plasmids are purified from the selected *E. coli* using standard techniques in the art. A common marker

would allow the isolation of both plasmids in a single step, saving time and expense involved in separate isolations.

In the method of the present invention, a protein-protein linkage map is generated and stored as an array, without the need for subcloning or sequencing the 5 X or Y inserts. The present invention also provides a proteomic array of interactive protein pairs, and nucleic acid encoding the pairs and is also referred to herein as an archive. The interactive protein pair information can be stored as a database comprising at least one of said arrays, coupled with information describing the linkage between the members of said array. For example, each selected two-hybrid 10 clone harbors a bait plasmid and a prey plasmid. These plasmids can be stored together in the same location of the two dimensional array, on the bait plasmids from all two-hybrid clones can be stored in one array or set of arrays while the prey plasmids are stored in a separate array or set of arrays. The bait and prey arrays will be linked by information such that identifying a given bait or prey plasmid reveals 15 the location of the corresponding prey or bait plasmid, respectively.

The arrays of the present invention can be of any suitable size on any suitable substrate. In one embodiment of the present invention, the arrays are two dimensional. In another embodiment, the substrate is a plastic tray or plate comprising wells, such as a 96 well or 384 well plate. Said plates are well known in 20 the art. In another embodiment, the array can be a series of spots on a substrate, such as nylon membrane, glass slide, or photolithographic biochip. The amount of DNA in a given spot can be as little as nanogram quantities, however, less can be used depending on the sensitivity of the detection system. The number of spots in an array can be very large depending on the resolution of the spotting or printing apparatus 25 used.

The two-hybrid systems and proteomic arrays of the present invention can be combined a microarray system. As a result, differentially expressed genes can be identified in normal or disease states, or at particular stages of development without having to examine 50 billion potential interactions. Methods of making microarrays 30 are well known in the art and methods of identifying differentially expressed genes is

-13-

described in U.S. Serial No. 09/350,609, the teachings of which are incorporated herein by reference in their entirety.

In another embodiment of the present invention, a method is provided for selecting polypeptides capable of interacting *in vivo* with a polypeptide of interest, 5 wherein the interaction is dependent upon post-translational modification (3 protein, two-hybrid). The method comprises providing or generating arrays comprising a first plasmid partner comprising a library linked to nucleic acid sequence encoding a DNA binding domain and a second plasmid partner comprising the same or a second library linked to nucleic acid encoding a transcriptional activation domain, wherein 10 the first and second plasmid partners encode proteins that interact in the presence but not the absence of the third plasmid partner comprising at least one post-translational modifying enzyme. The expression of said enzyme is optionally under the control of an inducible transcriptional system. The first and second plasmid partners are selected by their ability to, in concert and in the presence of the expressed post- 15 translational modifying enzyme, activate transcription of one or more marker genes in a host cell. In another embodiment, the first and second plasmid partners encode proteins that interact in the absence but not in the presence of the third plasmid partner.

Plasmids or vectors that encode all or a portion of a polypeptide of interest 20 and polypeptides that interact with the polypeptide of interest are selected by contacting the array under conditions where the probe detectably hybridizes to complementary sequence, if present, within any of plasmids of the array. Plasmid partner or partners of the hybridized plasmid are identified (e.g., localized on the array) and optionally isolated, wherein said partner or partners encode a polypeptide 25 capable of interacting, under physiological conditions and in a post-translational modification dependent manner, with the polypeptide of interest.

The post-translational modifiers selected for use in the third dimension of the 3PTH system can be selected from known genes encoding desired members of the family. For example, genes encoding several protein kinases have been cloned, such 30 as PKA, SYK, p34cdc2, PKC and PI3 kinase and can be readily used in the method

of the present invention by one of ordinary skill in the art. Similarly, genes for phosphatases, glycosylation enzymes and endoproteases have been cloned and can be readily used in the method of the present invention.

In another embodiment of the present invention, the modification enzyme 5 encoded by the third plasmid is under the control of an inducible promoter such as MET25. Inducible promoters are well known in the art and can readily be incorporated into the method of the present invention. Other inducible systems include heat shock, GAL and tetracycline inducible promoter systems.

In one embodiment of the present invention, one or more post-translational 10 enzymes are used in the third dimension of the 3PTH system. In a yet another embodiment of the present invention, the genes encoding post-translational modifiers of the third dimension can be a library of genes encoding such proteins. A family of kinases, proteases, glycosylation enzymes or endoproteases representing all or a portion of the cellular complement of such proteins can be generated, for example 15 using PCR. For example, primers for PCR can be used that recognize known motifs in the class of post-translational modifier to be used in order to amplify all or a portion of the sequences encoding said modifiers. In one embodiment of the 3PTH method of the present invention, the third plasmid partner is not included in the arrays produced. In one embodiment, the first and second plasmid partners are 20 selected using selective markers that is not present on the third plasmid partner.

In another embodiment, of the present invention, at least one plasmid partner is generated from a normalized library. Libraries can be normalized, for example, as described by Sive and St. John (Nucleic Acids Res. 16:10937 (1988)) and in U.S. Serial No.: 60/067,992 the teachings of which are both incorporated herein by 25 reference in their entirety.

The plasmid partners can be generated by fusing the library sequences to DNA encoding one half of the selection complex e.g., the DNA binding domain sequence or transcription activation sequence such that a fusion protein comprising both segments is expressed. In one embodiment, the fusion is in frame between the 30 coding sequence of both segments. However, libraries containing some out of frame

-15-

fusions can be used, in which case the library is generally made with more clones. In one embodiment of the present invention, the library of the first plasmid partner is fused at its 5' end to the sequence encoding a DNA binding protein. In another embodiment of the present invention, the library of the first plasmid partner is fused 5 at its 3' end to the sequence encoding a DNA binding protein. Similarly, the library of the second plasmid partner can be fused at either its 5' or 3' end to the sequence encoding the other half of the selection complex; for example, if the first plasmid partner uses the DNA binding domain, then the second plasmid partner uses the DNA transcription domain to generate the second plasmid partner.

10 In one embodiment of the present invention, the library comprises cDNA, full-length cDNA, genomic DNA or DNA encoding a peptide library. These libraries are readily available from commercial sources or can be synthesized using techniques well known in the art. For example, full length libraries are produced using methods described in U.S. Serial No. 09/062,452 the teachings of which are incorporated  
15 herein by reference in their entirety.

The DNA binding protein and transcriptional activators used to generate the selection complex can be from any known transcriptional activation protein that binds DNA wherein the DNA binding domain binds in a sequence specific manner. Useful transcriptional activators are well known in the art. Particularly useful are  
20 those proteins where in the DNA activation domain and the DNA binding domain are separable at the DNA sequence level. In a further embodiment of the present invention, the DNA binding protein domain is selected from the group consisting of GAL4, lexA, GCN4 and ADR1. In another embodiment of the present invention, the transcription activation domain is selected from the group consisting of GAL4,  
25 GCN4, ADR1 and herpes simplex VP16.

The DNA binding site is typically placed upstream of a gene encoding a selectable marker for the host organism such that protein-protein interaction between the polypeptides encoded by the first and second partner plasmid results in transcription of the gene encoding the selectable marker. Selectable markers are well  
30 known in the art and include, for example, genes that render the host prototrophic for

a given nutrient and genes that encode enzymes that produce a color or fluorescent product when exposed to the appropriate substrate.

In one embodiment, yeast clones harboring plasmid partners that encode interacting polypeptides are selected by growing the fused two-hybrid host on medium lacking the nutrient required in the absence of transcription of the gene encoding the selectable marker. In another embodiment the fused two-hybrid hosts are grown on medium containing the appropriate colorimetric or fluorogenic substrate for the enzyme encoded by the selectable marker gene.

The two-hybrid hosts can be fused in batch. In one embodiment, the fused two-hybrid hosts are plated on the selective medium such that individual colonies are derived from individual fused hosts. Positive clones can be picked or isolated by hand or by robotic methods. Colony picking robots are well known in the art. In another embodiment, the fused two-hybrid hosts are contacted with the fluorogenic substrate and positive cells are selected using a fluorescence activated cell sorter.

Methods of fluorescence activated cell sorting are well known in the art.

Suitable hosts for the two-hybrid screen of the present invention include any transformable organism that can be grown as a single-celled organism. Such hosts include prokaryotes and eukaryotes. In particular eukaryotic hosts can be yeast and mammalian or other cell culture.

The arrays of the present invention can be generated using polynucleic acid libraries from any organism of interest, including prokaryotic, archebacterial and eukaryotic organisms.

The present invention is drawn to a composition comprising an array of plasmids comprising two or more plasmid partners wherein a first plasmid partner comprises a first library fused to a nucleic acid encoding a DNA binding domain, a second plasmid partner comprises the first or a second library fused to a nucleic acid sequence encoding a transcriptional activation domain, wherein the first and second plasmid partners are selected to be in the array by their ability to, in concert and in the absence of expression of said post-translational modifying enzyme, activate

transcription of one or more marker genes in a host cell, wherein the post-translational modifying enzyme is encoded by a third plasmid partner in the host cell.

The present invention is drawn to a composition comprising an array of plasmids comprising two or more plasmid partners wherein a first plasmid partner 5 comprises a first library fused to a nucleic acid encoding a DNA binding domain, a second plasmid partner comprises the first or a second library fused to a nucleic acid sequence encoding a transcriptional activation domain, wherein the first and second plasmid partners are selected to be in the array by their ability to, in concert and in the presence of expression of said post-translational modifying enzyme, activate 10 transcription of one or more marker genes in a host cell, wherein the post-translational modifying enzyme is encoded by a third plasmid partner in the host cell.

Methods for reducing the false negatives include making different libraries. For example, random primed cDNA two-hybrid libraries can be constructed to obtain small protein domains which may be buried in the intact proteins in a specific 15 condition. Second, the protein fusion interface can be changed. Traditionally, the DNA binding domain and activation domain are located in the N-terminus of the fusion protein. New libraries can be constructed with the DNA binding domain and activation domain located at its C-terminus, so that the N-terminus of the bait protein can be free for its interactions. Third, the libraries for the first and second plasmid 20 partner can be enriched for full-length genes. Furthermore, several "cytoplasm two-hybrid systems" have been developed. Cytoplasm two-hybrid systems can be integrated into the 3PTH system to cover those proteins which do not interact properly in the nucleus.

The invention will be further illustrated by the following non-limiting 25 example.

## EXAMPLES

### Example 1: Three-Protein Two Hybrid Screen

#### Plasmid Vectors:

5 Two vectors with three drug resistance genes are constructed. Each vector carries an unique *E.coli* selection marker such as Zeocin or DHFR (DHFR represents DiHydroFolate Reductase and confers resistant to Trimethoprin). The vectors also carry an additional common selection marker,  $\beta$ -lactamase. The drug resistant gene specific to each vector increases the efficiency of recovering the plasmids that are  
10 positive. The cycloheximide counterselection system (Harper *et al.*, *Cell*, 75:805-816 (1993)) can be used to optimize selection.

The DNA-binding domain (DB) vector (or first plasmid partner) is constructed by inserting the Zeocin resistant gene into pGBT9 (Bartel *et al.*, *Methods Enzymol.*, 254:241-263 (1995)) or pDBTrp (Vidal, Bartel and Fields, Eds. Oxford Univ. Press 109, (1997)). pACT2 constitutes the basis of the activation domain (AD) vector (second plasmid partner) with the addition of the DHFR gene. pGBT9 and pDBTrp are selected because they yield low levels of false positives. While not wishing to be bound by theory, this may be due to their low level of gene expression. The main source of false positives usually originates from the activation of the  
20 DB-vector reporter gene by itself pDBTrp is a centromere-based (low copy number) expression plasmid with the full length ADH1 promoter. pGBT9 is a two micron-based (high copy number) expression vector with a truncation to give a minimal activity ADH1 promoter.

#### 25 Yeast Strains:

The promoter strength of the reporter gene and the expression level of the two hybrid proteins determine the sensitivity of two-hybrid system. Thus, the selection of the yeast host strain is critical for success. In general, the upstream activating sequence (UAS) of GAL1 is stronger than GAL2 UAS , and GAL2 UAS is stronger  
30 than the synthetic GAL4 binding site consensus sequence (UAS G17-mer). The available host strains shown below are compared and the optimal pair is selected.

-19-

PJ69-2A: MAT<sub>a</sub>, trp1-901, leu2-3,112, ura3-52, his3-200, gal4, gal80,  
LYS2::GAL1<sub>UAS</sub>-GAL1<sub>TATA</sub>-HIS3, GAL2<sub>UAS</sub>-GAL2<sub>TATA</sub>-ADE2  
(James *et al.*, *Genetics* 144:1425-1436 (1996))

5 Y187: MAT<sub>a</sub>, ura3-52, his3-200, ade2-101, trp1-901, leu2-3,112, met-, gal4,  
gal80, URA3:: GAL1<sub>UAS</sub>-GAL1<sub>TATA</sub>-lacZ (Harper *et al.*, *Cell*, 75:805-  
816 (1993)).

10 MaV103: MAT<sub>a</sub>, leu2-3,112, trp1-901, his3\_200, ade2-101, gal4, gal80,  
SPAL10::URA3, GAL1(GAL1<sub>UAS</sub>)::lacZ, HIS3(GAL1<sub>UAS</sub>)::HIS3  
@LYS2 (Vidal *et al.*, *Proc. Natl. Acad. Sci. USA* 93:10315-10328  
(1996)).

15 MaV203: MAT<sub>a</sub>, leu2-3,112, trp1-901, his3\_200, ade2-101, gal4, gal80,  
SPAL10::URA3, GAL1(GAL1<sub>UAS</sub>)::lacZ, HIS3(GAL1<sub>UAS</sub>)::HIS3  
@LYS2 (Vidal, 1997 )

The host strain pair PJ69-2A /Y187 uses two different promoters (GAL1 and GAL2)  
on three different reporters (HIS3, ADE2, lacZ). The yeast pair MaV103 and  
20 MaV203 has SPAL10(UAS G17-mer) and GAL1 as the promoters in front of  
reporters URA3, HIS3, and lacZ. The sensitivity of SPAL10 (UAS G17-mer)  
promoter to GAL1 and GAL2 is compared by using a group of known interacting  
proteins with different affinities (Table I), then selecting the strain with stronger  
promoters.

-20-

TABLE I : Examples of Known Interacting Pairs

	Hybrid #1	Hybrid #2	Interaction Strength
5	Pair 1 human RB (aa302-928)	human E2F (aa342-437)	weak (Vidal <i>et al.</i> , <i>Proc. Natl. Acad Sci USA.</i> 93(19):10315-20 (1996))
	Pair 2 Drosophila DP (aa1-377)	Drosophila (aa225-433)	moderate (Du <i>et al.</i> , <i>Genes Dev.</i> 10(10):1206-18 (1996))
10	Pair 3 cFos (aa132-211)	cJun (aa250-325)	strong (Chevray & Nathans, <i>Proc. Natl. Acad Sci., USA.</i> , 89 (13):5789-93 (1992))
	Pair 4 murine p53 (aa72-390)	SV40 T antigen (aa87-708)	moderate (Iwabuchi <i>et al.</i> , <i>Oncogene</i> , 8(6):1693-6 (1993))
	Pair 5 yeast SNF1	yeast SNF4	weak (Fields & Song, <i>Nature</i> 340 : 245-6 (1989))
15	Pair 6 murine SNK	human CIB	moderate (Yuan & Erikson, unpublished)

## Library Construction:

A series of brain cDNA libraries is constructed using AlphaGene's  
 20 normalization and FLEX™ (Full-Length Expressed gene) cDNA library construction  
 technologies U.S. Serial No.s: 09/062,452, the teachings of which are incorporated  
 herein in their entirety. Plasmid pGBT9-Zeo has been constructed and tested by  
 constructing a human fetal brain library with a titer of  $1.8 \times 10^6$  primary clones. The  
 libraries were normalized. Table II summarizes the results of  $\alpha$ -tubulin and  $\beta$ -actin  
 25 abundance comparisons in two cDNA libraries, constructed from the same fetal brain

mRNA. The protocol for library normalization is an improvement of the Sive and St. John protocol (Sive & St. John, 1988;). A short hybridization, corresponding to an estimated Cot of four, was carried out before addition of streptavidin to remove double-stranded DNA. Hybrid selection with alpha-tubulin and beta actin was 5 performed, followed standard procedures. In each hybrid selection an average of two thousand colonies were examined.

TABLE II : Library Normalization Data

	Normalized Library	Control Library	Improvement
$\alpha$ -tubulin (%)	0.1	0.9	9X
$\beta$ -actin (%)	0.1	0.7	7X

15

#### Pre-screening:

The number of false positive clones is reduced by performing a prescreen. URA counterselection is performed to remove the false positive signal from the DNA-binding domain alone. The DNA-binding domain library are transformed 20 separately into strain MaV203 and *ura*<sup>r</sup> colonies are selected on 5-FOA plates. All surviving colonies are used for the two-hybrid interaction screening procedure.

#### Interaction Screen:

Yeast mating (Bendixen *et al.*, *Nucleic Acids Res.* 22(9):1778-9, 1994) and 25 plasmid transformation followed by nutritional selection are used in the two-hybrid interaction screen. The DNA-Binding domain (DB) library is transformed into strain PJ69-2 (a mating type a strain) and the Activation Domain (AD) library transformed into strain Y187 (a mating type  $\alpha$   $\sigma\tau\rho\alpha\gamma\psi$ ). The  $\alpha$  and a transformants are mated with subsequent nutritional selection. Plasmids that grow after nutritional selection 30 are isolated. Optimization of the mating/transformation step is critical because yeast cells, unlike *E. coli*, can acquire multiple plasmids following transformation. The

amount of DNA used in transformation is varied to alter the number of plasmids transformed into cells.

For an initial test, pilot scale experiments are performed using two different approaches. Tests with 10 known interacting pairs with various affinities are 5 conducted. The interactions among these 10 pairs are studied by 1) A matrix mating --- the interaction of every possible pair (100 pairs in combination is examined); 2) A "library vs. library" or batch screen --- the 10 clone pairs are mixed as two "mini-libraries" (one DB library and one AD library) followed by an interaction screen. The percentage of false positives and false negatives is determined for each 10 selection marker.

Following the initial tests, a small scale genome wide interaction screen is performed with a pair of two-hybrid FLEX™ cDNA libraries. The ADE selection marker was chosen. To tighten the screen an additional marker, the *E. coli lacZ* gene can be used. There are two possible alternatives to select for the clones. In one 15 scenario, the clones surviving nutritional selection are robotically picked to 96 well plates, followed by a liquid  $\beta$ -galactosidase assay with a chemiluminescent substrate (Campbell *et al.*, 1995). In the second scenario, a  $\beta$ -galactosidase filter assay is performed and the blue colonies are robotically distributed in 96 well plates.

## 20 Plasmid Retrieval

Isolation of plasmids from yeast is not trivial. The problem is particularly difficult when working with large plasmids (>6 kb). Low yields and genomic contamination are common. To rapidly isolate the plasmid, 1.5 ml of saturated yeast cells were spun down and lysed in 10  $\mu$ l of Lyticase for 60 min at 37° C, then 10  $\mu$ l 25 of 20% SDS was added with vigorous vortexing to help the cell lysis. The cells were put through one freeze/thaw cycle to ensure complete lysis. The whole cell lysate was passed through a spin column. The column beads of the high throughput spin column were purchased from Pharmacia Biotech (Sephacryl S-1000). The eluate from the spin column containing the purified DNA was collected for the 30 transformation into *E. coli* for amplification. After the plasmid is isolated from

-23-

yeast, the DNA is transformed back into *E.coli* for amplification. A multi-head electroporator from BTX, Genetronics, is used to increase the throughput. The two vector/three selectable markers system provides for efficient plasmid recovery.

## 5 Confirmation

Multiple *E. coli* transformants are picked, plasmid DNAs are isolated, and transformed back into yeast strains to confirm the interactions. Confirmation is necessary since yeast can carry multiple plasmids. It is worth noting that optimization of the plasmid transformation procedure may significantly lower the likelihood that a yeast cell carries more than one type of plasmid.

### Construction of Arrays and Identification of Interacting Clones by Hybridization Amplification of the DNAs

A library versus library two-hybrid screen was performed as described above.  
15 The DNA-binding domain library was prescreened to remove clones that can activate the reporters in the absence of protein-protein interaction. Clones that passed the prescreen were mated with clones from an activation domain library. A portion of the mated cells were selected for those carrying protein-protein interactions.  
Plasmids from a portion of the selected colonies were retrieved from yeast cells and  
20 amplified in *E. coli* then extracted using standard molecular biology protocol.

One pair of interaction plasmids plus 10 known plasmids were spotted onto microarray slides in a duplicate fashion. Two independent clones from the 10 known genes were labeled with fluorescent CY3 or Cy5 for use as probes to determine whether the spotted plasmids can be correctly identified on microarray slides.  
25 Approximately 1 µg of each plasmid DNA was resuspended in 5X SSC buffer for printing (spotting) onto the slides. The printing procedure was followed according to the manufacturer's instructions. Approximately 6ng of plasmid DNA was printed onto a single spot in duplicate.

-24-

Table VI

Locations (duplicate)	Plasmid Clone Name	Insert Description	Comment
A1, B1	YY367-1	B11 in pGBT9 vector	B11 is a novel gene previously identified as interacting with Snk (at A4 and B4)
5 A2, B2	F2	F2 in pGBT9	Interacts with F14 at A5 and B5
A3, B3	Alpha 4	Alpha 4 in pGBT9	Interacts with PP6 at A6 and B6
A4, B4	YY89-1	Snk in an activation domain vector (pGAD424)	Snk, a protein kinase, interacts with B11 at A1 and B1
A5, B5	F14	F14 in pGAD vector	Interacts with F2 at A2 and B2
10 A6, B6	PP6	PP6 in pGAD vector	Interacts with Alpha 1 At A3 and B3
A7, B7	YY313-9	B11 in pGAD vector	B11 is a novel gene previously identified as interacting with Snk (at A4 and B4)
A8, B8	TD-1	SV40 large T-antigen in pACT2	
A9, B9	B75	B75 in pGAD vector	
A10, B10	A18	A18 in pGAD vector	
C1, C3	2-hybrid clone 1	An unknown clone in DAN-binding domain vector	interacts with clone2 at C2 and C4
15 C2, C4	2-hybrid clone2	An unknown clone in activation domain vector	interacts with clone1 at C1 and C3

-25-

### Fluorescent Probe Synthesis

Genes B11 and Snk were excised from clones YY313-9 and YY8-11 respectively and the inserts were isolated from agarose gel by centrifugation.

Approximate 25ng of denatured DNAs were labeled by Cy3 and Cy5 dCTP

5 (purchased from Amersham Biotech) in a reaction containing random primer mixture and reaction buffer (both provided by High Prime DNA Labeling Kit from Boehringer Mannheim), 25 $\mu$ M 2'-deoxyadenosine-5' - triphosphate, 25 $\mu$ M 2'thymidine-5'-triphosphate, 25 $\mu$ M 2'-deoxyguanosine-5'-triphosphate, 5 $\mu$ M 2'-deoxycytidine-5'-triphosphate and 20 $\mu$ M Cy3 or Cy5 labeled 2'-deoxycytidine-5'-triphosphate and 4 U of Klenow polymerase. The reaction was incubated at 37° C for 45 min and stopped by incubating at 65° C for 10 min. The probes were purified by standard ethanol precipitation and resuspended in 10  $\mu$ l of hybridization buffer (6 X SSC, 5X Denhart's solution, 2% SDS, 0.1  $\mu$ g/ $\mu$ l of yeast tRNA).

### 15 Hybridization

2  $\mu$ l each of Cy3 probe and Cy5 probe were combined for hybridizing the DNA on each of glass slide. The slides were placed in slide chambers with a towel wet with 2 X SSC. They were brought up to 80 ° C for 10 min and then immediately put on ice to denature the DNA, hybridized at 62° C for 6 hours, then washed to remove 20 the unhybridized probes by 2X SSC, dried, and scanned by GenePix 4000 Microarray Scanner from Axon Instruments.

-26-

## Results

1. To evaluate the spotting procedure, a Cy5 or Cy3 labeled probe containing common vector sequences was hybridized to the DNA on glass slide. Figure 4  
5 showed that all DNAs were attached onto slide.

2. To localize the clone Snk

A Snk probe either labeled by Cy3 or Cy5 was hybridized to the slide. Figure  
10 5 shows Snk probe hybridizes both A4 and B4 DNAs which are the Snk clones.

3. To localize the clone B11:

15 A B11 probe either labeled by Cy3 or Cy5 was hybridized to the slide. Figure 6 shows the B11 probe hybridizes locations A1, B1, A7, B7 (location 1 represents B11 in pGBT9 and location 7 represents B11 in the pGAD vector).

Thus, a specific DNA probe can correctly identify homologous DNA on an array  
20 with little or no background. For example, if Snk is the polypeptide of interest, a labeled Snk polynucleotide is used to probe the interaction array. The hybridization identifies A4 and B4. From the linkage information shown in Table VI, the clone at A1 and B1 (B11) is identified as a Snk interacting clone. The linkage information is provided by the arrays of the present invention. This method can be used repetitively  
25 with newly identified interacting clones as the probes, to draw a protein interaction map and establish biological interaction pathways.

### Example 2: Construction of Two Hybrid Arrays

#### Plasmid vectors:

A new vector is constructed to be used as the third plasmid partner. This vector carries URA3 marker, a yeast 2 $\mu$  origin of replication, a yeast nuclear localization signal, multiple cloning sites, ampicillin selection marker and Col E1 origin of replication. A yeast inducible promoter (Met25). A constitutive promoter (pADH) can also be used.

#### Yeast Strains:

10 A new  $\alpha$  mating type strain is constructed from Y187 the URA3 phenotype is reverted to ura3 by 5-Fluoroorotic Acid (5-FOA) counterselection. The desired genotype is (Mat $\alpha$ , ura3, his3, ade2, trp1, leu2, met, gal4 $\Delta$ , gal80 $\Delta$ , ura3::GAL1<sub>uas</sub>-GAL1<sub>TATA</sub>-lacZ). PJ69-2A (a mating type A strain) will be used in the mating assay as the second plasmid partner.

15

#### Library construction:

A series of brain cDNA libraries is constructed using technology described U.S. Patents 5,162,290, 5,643,766 and Serial No.: 09/062,452, the teachings of which are incorporated herein in their entirety. The bait library is cloned into the pGBT9 derived vector and the prey library is cloned into the PACT2-derived vector. Kinases are chosen for the third plasmid partner in 3PTH. Kinases are chosen to obtain sufficient activity. Kinases are selected based on the following criteria, either separately applied or applied in combination: (1) kinases that have been overexpressed in the host cell in the past; (2) kinases whose constitutive and/or inactive forms are available; (3) kinases which have homologous pathways in yeast (allowing activation in yeast by an endogenous activator if necessary); (4) kinases which are expressed in a tissue of interest (for example, brain tissue). The nucleic acid encoding the kinase or kinases are expressed under the control of an inducible promoter such as the MET25 inducible promoter.

-28-

The presence or absence of kinase activity under specified conditions is optimized using positive control pairs of proteins as shown in Table III. The first column represents the first hybrid protein, the second column represents the second hybrid protein, the third column represents the third plasmid partner (kinase) and the 5 fourth column represents the affinity of interaction after the hybrid protein is phosphorylated by the kinase listed in column 3.

Table III

	<b>Hybrid 1</b>	<b>Hybrid 2</b>	<b>Kinase</b>	<b>Interaction Level<sup>1</sup></b>
10	CREB	CBP	PKA	increase
	IgE receptor	SH2-B	Syk or Lyn	increase
	RGSZ1	Gzalpha	PKC	increase
	HsEg5	dynactin (p150)	P34cdc2	increase
	NMDA receptor	calmodulin	PKC	decrease
15	Mu2	CTLA-4	PI3	decrease

1. of phosphorylated form

#### 3PTH Library Screening:

Both bait and prey fusion protein containing plasmids are transformed into one 20 haploid yeast strain (MAT<sub>a</sub>, for example) and the kinase containing plasmid(s) are transformed into the other haploid strain (MAT<sub>a</sub>). Figure 3 is a flow chart of the 3PTH system.

#### Screen for Interactions that Occur Only in the Unphosphorylated Form:

25 Both the pGBT9 based library and the PACT2 based library DNA are transformed into ura3 MAT<sub>a</sub> cells having the ade<sup>-</sup> genotype. White (ADE<sup>+</sup>) colonies are picked and arrayed onto 96 well plates by a robot. A control panel, including positive and negative controls are also placed onto each plate. The arrays of cells are grown and replica plated onto the desired number of plates (e.g. the number of

-29-

kinases to be screened plus one plate for a negative control of empty kinase vector).

The kinase vectors (carrying the URA3 marker) are transformed into MAT $\alpha$  cells.

The MAT $\alpha$  cells and MAT $\alpha$  cells, transformed as described above, are mated in batch fashion. White colonies are selected and the GBT9 and pGAD424 fusion plasmids are recovered by Zeocin and Ampicillin selection, respectively, using standard plasmid isolation techniques. The desired clones have the following phenotypes:

Table IV

	Plasmid	Color in 3PTH Assay
10	GBT9 alone	red
	GAD424 alone	red
	GBT9 + GAD424	white
	GBT9 + GAD424 + kinase	red

15 DNA encoding proteins that interact with a polypeptide of interest only in the absence of phosphorylation are selected and isolated by probing the array of plasmids recovered above with DNA encoding the polypeptide of interest.

#### Screen for Interactions that Occur Only in the Presence of Phosphorylation

20 The initial screen for interacting proteins is performed as described above except red transformed MAT $\alpha$  colonies are picked by the robot. The kinase transformed MAT $\alpha$  cells are mated to the selected, transformed MAT $\alpha$  cells in batch fashion. The HIS+ and ADE+ colonies are arrayed onto 96 well plates. The arrays are replicated onto two plates. On one plate, kinase expression is turned off by adding methanol to 25 turn off the MET2 promoter, or by adding 5-FOA to counter select the URA plasmid. The cells on the other plate are allowed to express the kinase. Colonies that are white on the kinase+ plate and red on the kinase- plate are selected. Plasmids are recovered as described above. The desired clones have the following phenotypes:

30

-30-

Table V

Plasmid	Color in 3PTH Assay
GBT9 alone	red
GAD424 alone	red
GBT9 + GAD424	red
Kinase + GBT9	red
Kinase + GAD424	red
GBT + GAD424 + kinase	white

10 DNA encoding proteins that interact with a polypeptide of interest only in the presence of phosphorylation are selected and isolated by probing the array of plasmids selected above with DNA encoding the polypeptide of interest.

#### EQUIVALENTS

15 Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

## CLAIMS

What is claimed is:

- 5 1. A method of identifying polynucleic acids encoding at least one polypeptide capable of interacting, *in vivo* with a polypeptide of interest comprising:
  - a) contacting at least one array of plasmids with a probe, wherein:
    - i) said probe encodes the polypeptide of interest or fragment thereof, wherein said probe hybridizes to complementary sequence, if present, within any of the plasmids, and wherein:
    - 10 ii) said array comprises two or more plasmid partners, wherein a first plasmid partner comprises a first library fused to a first nucleic acid sequence encoding a first half of a selection pair and a second plasmid partner comprises the same or a second library fused to a second nucleic acid sequence encoding a second half of a selection pair and wherein the plasmid partners are selected to be in the array by their ability to, in concert, 15 activate the selection pair in a host cell, and
  - b) identifying the partner or partners to said hybridized plasmid, 20 wherein said partner or partners encode a polypeptide capable of interacting, *in vivo* with the polypeptide of interest.
2. The method of Claim 1, wherein the selection pair comprises a DNA binding domain and a transcriptional activation domain. 25
3. The method of Claim 2, wherein the DNA binding domain sequence is selected from the group consisting of: GAL., lexA, GCN4 and ADR1.
4. The method of any one of Claims 2 or 3, wherein the transcription activation 30 domain sequence is selected from the group consisting of: GAL., GCN4, ADR1 and herpes simplex VP16.

-32-

5. The method of any one of Claims 1 through 4, wherein the first library is normalized.
6. The method of any one of Claims 1 through 5, wherein the second library is normalized.
7. The method of any one of Claims 1 through 6, wherein the library of the first plasmid partner is fused at its 5' end to the first nucleic acid sequence.
- 10 8. The method of any one of Claims 1 through 6, wherein the library of the first plasmid partner is fused at its 3' end to the first nucleic acid sequence.
9. The method of any one of Claims 1 through 8, wherein the library of the second plasmid partner is fused at its 3' end to the second nucleic acid sequence.
- 15 10. The method of any one of Claims 1 through 8, wherein the library of the second plasmid partner is fused at its 5' end to the second nucleic acid sequence.
- 20 11. The method of any one of Claims 1 through 10, wherein the plasmid partners are in separate linked arrays.
- 25 12. The method of any one of Claims 1 through 10, wherein the plasmid partners are together in the same array.
13. The method of any one of Claims 1 through 12, wherein a) further comprises a third plasmid comprising a sequence encoding at least one post-translational modifying enzyme.
- 30 14. The method of Claim 13, wherein the post-translational modifying enzyme is under the control of an inducible promoter system.

15. The method of Claims 13 or 14, wherein the post-translational modifying enzyme is selected from the group consisting of kinases, phosphatases, glycosylation enzymes and endoproteases.
- 5 16. The array of any one of Claims 1 through 15, wherein the array comprises at least one set of plasmids comprising two or more plasmid partners, wherein a first plasmid partner comprises a first library fused a first nucleic acid sequence encoding a first half of a selection pair and a second plasmid partner comprising the same or a second library fused to a second nucleic acid sequence encoding a second half of a selection pair, and wherein the plasmid partners are selected to be in the array by their ability to, in concert, activate the selection pair in a host cell.
- 10 17. A method of identifying polynucleic acids encoding at least one polypeptide capable of interacting, *in vivo*, with a polypeptide of interest, wherein the interaction is affected by post-translational modification, comprising:
  - a) contacting at least one array with a probe, wherein:
    - i) said probe encodes the polypeptide of interest or fragment thereof, wherein said probe hybridizes to complementary sequence, if present, within any of the plasmids, and wherein:
    - 20 ii) said array comprises and two or more plasmid partners, wherein a first plasmid partner comprises a first library fused to a first nucleic acid sequence encoding a first half of a selection pair, a second plasmid partner comprising the first or a second library fused to a nucleic acid sequence encoding a second half of a selection pair and a third plasmid partner comprising a polynucleic acid sequence encoding at least one post-translational modifying enzyme, wherein the first and second plasmid partners are selected by their ability to, in concert activate the selection pair in a host cell,
  - 25 b) identifying the partner or partners to said hybridized plasmid,
- 30

wherein said partner or partners encode a polypeptide capable of interacting with the polypeptide of interest.

18. The method of Claim 17, wherein the selection pair comprises a DNA binding domain and a transcriptional activation domain.  
5
19. The method of Claim 18, wherein the DNA binding protein domain sequence is selected from the group consisting of: GAL., lexA, GCN4 and ADR1.
- 10 20. The method of any one of Claims 18 or 19, wherein the transcription activation domain sequence is selected from the group consisting of: GAL., GCN4, ADR1 and herpes simplex VP16.
- 15 21. The method of any one of Claim 17 through 20, wherein the first library is normalized.
22. The method of any one of Claims 17 through 21, wherein the second library is normalized.
- 20 23. The method of any one of Claims 17 through 22, wherein the library of the first plasmid partner is fused at its 5' end to the first nucleic acid sequence.
24. The method of any one of Claims 17 through 22, wherein the library of the first plasmid partner is fused at its 3' end to the first nucleic acid sequence.  
25
25. The method of any one of Claims 17 through 24, wherein the library of the second plasmid partner is fused at its 3' end to the second nucleic acid sequence.
- 30 26. The method of any one of Claims 17 through 24, wherein the library of the second plasmid partner is fused at its 5' end to the second nucleic acid sequence.

-35-

27. The method of any one of Claims 17 through 26, wherein the plasmid partners are in separate linked arrays.
28. The method of any one of Claims 17 through 26, wherein the plasmid partners  
5 are together in the same array.
29. The method of any one of Claims 17 through 28, wherein the post-translational modifying enzyme is selected from the group consisting of kinases, phosphatases, glycosylation enzymes and endoproteases.  
10
30. The method of any one of Claims 17 through 29, wherein the post-translational modifying enzyme is under the control of an inducible promoter system.  
15
31. The method of Claim 30, wherein the inducible transcriptional system is selected from the list consisting of: MET25, heat shock, GAL and tetracycline sensitive promoters.  
20
32. The method of any one of Claims 17 through 31, wherein the interaction is inhibited by the post-translational modification.  
25
33. The array of any one of Claims 17 through 32, wherein the array comprises at least one set of plasmids comprising two or more plasmid partners, wherein a first plasmid partner comprises a first library fused to a first nucleic acid sequence encoding a first half of a selection pair and a second plasmid partner comprising the same or a second library fused to a second nucleic acid sequence encoding a second half of a selection pair, and wherein the plasmid partners are selected to be in the array by their ability to, in concert, activate the selection pair in a host cell.  
30
34. A composition comprising at least one array of plasmids comprising two or more plasmid partners, wherein a first plasmid partner comprises a first library fused to a first nucleic acid sequence encoding a first half of a selection pair

and a second plasmid partner comprising the same or a second library fused to a second nucleic acid sequence encoding a second half of a selection pair, and wherein the plasmid partners are selected to be in the array by their ability to, in concert, activate the selection pair in a host cell.

5

35. A composition comprising an array of plasmids comprising two or more plasmid partners wherein a first plasmid partner comprises a first library fused to a nucleic acid encoding a DNA binding domain, a second plasmid partner comprises the first or a second library fused to a nucleic acid sequence encoding a transcriptional activation domain, wherein the first and second plasmid partners are selected to be in the array by their ability to, in concert and in the absence of expression of said post-translational modifying enzyme, activate transcription of one or more marker genes in a host cell, wherein the post-translational modifying enzyme is encoded by a third plasmid partner in the host cell.
- 10  
15
36. A composition comprising an array of plasmids comprising two or more plasmid partners wherein a first plasmid partner comprises a first library fused to a nucleic acid encoding a DNA binding domain, a second plasmid partner comprises the first or a second library fused to a nucleic acid sequence encoding a transcriptional activation domain, wherein the first and second plasmid partners are selected to be in the array by their ability to, in concert and in the presence of expression of said post-translational modifying enzyme, activate transcription of one or more marker genes in a host cell, wherein the post-translational modifying enzyme is encoded by a third plasmid partner in the host cell.
- 20  
25
37. The method of any one of Claims 34 through 36, wherein the selection pair comprises a DNA binding domain and a transcriptional activation domain.

-37-

38. The composition of Claims 37, wherein the DNA binding protein domain sequence is selected from the group consisting of: GAL., lexA, GCN4 and ADR1.
- 5 39. The composition of Claims 37 or 38, wherein the transcription activation domain sequence is selected from the group consisting of: GAL., GCN4, ADR1 and herpes simplex VP16.
- 10 40. The composition of any one of Claims 34 through 39, wherein the first library is normalized.
41. The composition of any one of Claims 34 through 40, wherein the second library is normalized.
- 15 42. The composition of any one of Claims 34 through 41, wherein the library of the first plasmid partner is fused at its 5' end to the first nucleic acid sequence.
- 20 43. The composition of any one of Claims 34 through 41, wherein the library of the first plasmid partner is fused at its 3' end to the first nucleic acid sequence.
44. The composition of any one of Claims 34 through 42, wherein the library of the second plasmid partner is fused at its 3' end to the second nucleic acid sequence.
- 25 45. The composition of any one of Claims 34 through 42, wherein the library of the second plasmid partner is fused at its 5' end to the second nucleic sequence.
46. The composition of any one of Claims 34 through 45, wherein the plasmid partners are in separate linked arrays.
- 30 47. The composition of any one of Claims 34 through 45, wherein the plasmid partners are together in the same array.

48. The composition of any one of Claims 35 through 47, wherein the post-translational modifying enzyme is selected from the group consisting of kinases, phosphatases, glycosylation enzymes and endoproteases.
- 5 49. The composition of any one of Claims 35 through 48, wherein the post-translational modifying enzyme is under the control of an inducible promoter.
50. The composition of Claim 49, wherein the inducible promoter is selected from the list consisting of: MET25, heat shock, GAL and tetracycline sensitive  
10 promoters.
51. A kit comprising at least one array of plasmids comprising two or more plasmid partners, wherein a first plasmid partner comprises a first library fused to a first nucleic acid sequence encoding a first half of a selection pair and a second plasmid partner comprising the same or a second library fused to a second nucleic acid sequence encoding a second half of a selection pair, and wherein the plasmid partners are selected to be in the array by their ability to, in concert, activate the selection pair in a host cell, buffers for hybridizing polynucleic acids of interest to said array, and instructions for hybridization.  
15
- 20 52. A method of generating an array of plasmids comprising:
  - a) conducting a two-hybrid screen, wherein a bait plasmid comprises a cDNA library and a prey plasmid comprises the same or a second cDNA library
  - 25 b) selecting positive two-hybrid clones and
  - c) immobilizing the bait and prey plasmids from said positive clones on a solid support at known locations,  
thereby generating an array of plasmids.




Fig. 1

2/6






FIG. 2

**Fig. 3**

4/6





Fig. 4


BEST AVAILABLE COPY

5/6



C B A

Cy5




C B A

Cy3

Fig. 5


**BEST AVAILABLE COPY**

6/6



C B A

Cy5



C B A

Cy3

Fig. 6

BEST AVAILABLE COPY

# INTERNATIONAL SEARCH REPORT

Intern. .... Application No  
PCT/US 00/02974

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C12Q1/68 C12N15/10

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12Q C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FROMONT-RACINE M ET AL: "TOWARD A FUNCTIONAL ANALYSIS OF THE YEAST GENOME THROUGH EXHAUSTIVE TWO-HYBRID SCREENS" NATURE GENETICS, US, NEW YORK, NY, vol. 16, 1 July 1997 (1997-07-01), pages 277-282, XP000770741 ISSN: 1061-4036 the whole document ---	1-52
Y	FIELDS S ET AL: "THE TWO-HYBRID SYSTEM: AN ASSAY FOR PROTEIN-PROTEIN INTERACTIONS" TRENDS IN GENETICS, NL, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 10, no. 8, 1 August 1994 (1994-08-01), pages 286-292, XP000647708 ISSN: 0168-9525 the whole document ---	1-52
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

24 November 2000

Date of mailing of the international search report

04/12/2000

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Knehr, M

# INTERNATIONAL SEARCH REPORT

Intern. Application No  
PCT/US 00/02974

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WODICKA ET AL: "GENOME-WIDE EXPRESSION MONITORING IN SACCHAROMYCES CEREVISIAE"          NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US,          vol. 15, December 1997 (1997-12), pages          1359-1367, XP002100297          ISSN: 1087-0156          the whole document</p> <p>---</p>	
A	<p>LECRENIER ET AL: "TWO-HYBRID SYSTEMATIC SCREENING OF THE YEAST PROTEOME"          BIOESSAYS, GB, CAMBRIDGE,          vol. 20, no. 1, January 1998 (1998-01),          pages 1-5-6, XP002100659          ISSN: 0265-9247          the whole document</p> <p>---</p>	
A	<p>R J CHO ET AL: "Parallel analysis of genetic selections using whole genome oligonucleotide arrays"          PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, US,          vol. 95, no. 7,          31 March 1998 (1998-03-31), pages          3752-3757, XP002146711          ISSN: 0027-8424          the whole document</p> <p>---</p>	
A	<p>JAMES P ET AL: "Genomic libraries and a host strain designed for highly efficient two-hybrid selection in yeast"          STN MEDLINE,          XP002130070          the whole document</p> <p>---</p>	
A	<p>DE 196 28 894 A (HAGENMAIER HANS PAUL)          22 January 1998 (1998-01-22)          the whole document</p> <p>-----</p>	

**INTERNATIONAL SEARCH REPORT**

## Information on patent family members

Intern .... Application No  
PCT/US 00/02974

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 19628894 A	22-01-1998	WO 9803676 A	29-01-1998